

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 February 2002 (07.02.2002)


PCT

(10) International Publication Number
WO 02/10158 A2

- (51) International Patent Classification⁷: **C07D 405/14**, A61K 31/404, C07D 403/04, 403/14 (74) Agent: **POPPE, Regina**; Grenzacherstrasse 124, CH-4070 Basle (CH).
- (21) International Application Number: **PCT/EP01/08293**
- (22) International Filing Date: **18 July 2001 (18.07.2001)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data: **60/221,058** **27 July 2000 (27.07.2000)** **US**
- (71) Applicant: **F. HOFFMANN-LA ROCHE AG [CH/CH]**; Grenzacherstrasse 124, CH-4070 Basle (CH).
- (72) Inventors: **GONG, Leyi**; 2259 Armada Way, San Mateo, CA 94404 (US). **GRUPE, Andrew**; 554 Jeter Street, Redwood City, CA 94062 (US). **PELTZ, Gary, Allen**; 110 Danbury Lane, Redwood City, CA 94062 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ~~ZW~~), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).



[Continued on next page]

(54) Title: **3-INDOLYL-4-PHENYL-1H-PYRROLE-2,5-DIONE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3BETA**



(57) Abstract: The present invention relates to 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives of Formula (I), wherein R¹ to R⁶ have the value given in the specification. The compounds are useful as inhibitors of glycogen synthase kinase-3 β and, therefore, may be used for the treatment of GSK-3 β mediated diseases.

B
Relative Expression of TCF7 in CD4 T-cells



BEST AVAILABLE COPY

WO 02/10158 A2

WO 02/10158 A2



Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

3-Indolyl-4-Phenyl-1H-Pyrrole-2,5-Dione Derivatives as Inhibitors of
Glycogen Synthase Kinase-3Beta

The present invention is directed to 3-indolyl-4-phenyl-1H-pyrrole-2,5-
dione derivatives that inhibit glycogen synthase kinase-3 β (GSK-3 β) and are
therefore useful in the treatment of mammals having disease states mediated by it.
The present invention is also directed to medicaments containing these compounds,
methods for preparing them, and their use, in particular for the treatment of
diseases characterized by excess Th2 cytokines and/or an excess IgE production.

Glycogen synthase kinase (GSK) is a serine/threonine kinase for which two
isoforms, α and β , have been identified. Glycogen synthase kinase -3 β (GSK-
3 β) was originally identified as a protein kinase which phosphorylated and
inactivated glycogen synthase, a key enzyme regulating insulin-stimulated
glycogen synthesis (see Embi et al., *Eur. J. Biochem.* 107, 519-527, (1980); Rylatt
et al., *Eur. J. Biochem.* 107, 529-537, (1980); and Vandenheede et al., *J. Biol.*
Chem. 255, 11768-11774, (1980)). Subsequently, it was discovered that GSK-3 β is
inhibited upon insulin activation thereby allowing the activation of glycogen
synthase. Therefore, inhibition of GSK-3 β stimulates insulin-dependent processes
and is useful in the treatment of type 2 diabetes which is characterized by decreased
sensitivity to insulin and an increase in blood glucose level. A number of drugs
such as 5-iodotubercidin®, metformin®, troglitazonem®, have been used to treat
diabetes. These drugs however have limited application because metformin® can
cause hypoglycemia, troglitazonem® can cause severe hepatotoxicity and 5-
iodotubercidin®, a GSK-3 inhibitor, inhibits other serine/threonine and tyrosine
kinases.

Recently, it has been discovered that GSK-3 β plays a role in pathogenesis
of Alzheimer's disease (see Lovestone et al., *Current Biology*, 4, 1077-86 (1994),
Brownlees et al., *Neuroreport*, 8, 3251-3255 (1997), Takashima et al., *PNAS* 95,
9637-9641 (1998), and Pei et al., *J Neuropathol. Exp.*, 56, 70-78 (1997)) and
bipolar disorder (see Chen et al., *J. Neurochemistry*, 72, 1327-1330 (1999)). It has

also been discovered that GSK-3 β is involved in blocking of early immune response gene activation via NF-AT and regulation of apoptosis (*see* Beals et al., *Science*, 275, 1930-33 (1997) and Pap, M. et al. *J. Biochem.* 273, 19929-19932, (1998)). Recently, it has also been discovered that GSK-3 β is required for the NF- κ B mediated survival response in the TNF- α signalling pathway involved in the proinflammatory response to infection (Hoeftlich et.al., *Nature*, 406, 86-90 (2000)).


Furthermore, GSK-3 β is also known to regulate the degradation of a protein (β -catenin) which controls the activity of TCF family of transcription factors (*see*, Dale, T. C., *Biochem. J.* 329, 209-223 (1998); Clevers, H. & van de Wetering, M., *Trends in Genetics* 13, 485-489 (1997); Staal, F.J.T. et al., *International Immunology* 11, 317-323 (1999)). The activity of this pathway has been shown to regulate the proliferation of colonic epithelial cells; and the biochemical data and clinical genetics demonstrate that it regulates the development of colon cancer.

Accordingly, there is a need for compounds that would inhibit GSK-3 β and thereby provide a means for combating diseases mediated by it. This invention fulfills this and related needs.

The present invention is directed to 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives that inhibit GSK-3 β and are therefore useful in the treatment of mammals having disease states mediated by it such as diabetes, Alzheimer's disease, bipolar disorder, ischemia, traumatic brain injury, and immunodeficiency.

In addition, Applicants have discovered that inhibition of GSK-3 β activity reduces the level of CD4+ T-helper 2 cells (Th2) which produce cytokines such as IL-4, IL-5, IL-13, and promote IgE production and eosinophil differentiation. This is an important discovery because it has been established that Th2 specific cytokines play a key role in the pathogenesis of diseases such as allergies and asthma. Therefore, the compounds of the present invention also provide a novel approach for the treatment of allergies and asthma.

Accordingly, in a first aspect, this invention is directed to 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives represented by Formula (I):



(I)

5 wherein:

R^1 and R^2 independently represent hydrogen, alkyl, halogen, haloalkyl, alkylthio, hydroxy, alkoxy, cyano, nitro, amino, acylamino, monoalkylamino, or dialkylamino;

10 R^3 represents hydrogen, alkyl, cycloalkyl, heteroalkyl, $-COR^7$ (wherein R^7 is hydrogen or alkyl), or phenyl optionally substituted with one or two substituents independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkylthio, hydroxy, alkoxy, cyano, nitro, amino, acylamino, monoalkylamino, and dialkylamino;

15 R^4 and R^5 independently represent hydrogen, alkyl, halogen, haloalkyl, alkylthio, hydroxy, alkoxy, cyano, nitro, amino, acylamino, monoalkylamino, or dialkylamino;

20 R^6 is heteroalkyl, heterocyclyl, heterocyclalkyl, heteroalkylsubstituted heterocyclyl, heteroalkylsubstituted cycloalkyl, heterosubstituted cycloalkyl, $-OR^8$, $-S(O)_nR^8$ (wherein n is an integer from 0 to 2; and R^8 is heteroalkyl, heteroalkyl, heterocyclyl, or heterocyclalkyl), $-NR^9R^{10}$ (wherein R^9 is hydrogen or alkyl and R^{10} is heterosubstituted cycloalkyl, heteroalkyl, heteroalkyl, heterocyclyl, or heterocyclalkyl), or $-X-(alkylene)-Y-Z$ (wherein X is a covalent bond, $-O-$, $-NH-$, or $-S(O)_{n1}-$ where $n1$ is an integer from 0 to 2, Y is $-O-$, $-NH-$, or $-S-$ and Z is heteroalkyl or $SiR^{11}(R^{12})(R^{13})$ where R^{11} , R^{12} and R^{13} are independently hydrogen or alkyl.), or R^6 together with R^4 forms a methylenedioxy or ethylenedioxy group
25 when they are adjacent to each other; or

a pharmaceutically acceptable salt thereof.

Also preferred are compounds which will be referred to the following under (i) which are compounds as defined above [these will be referred to in the

5 following under (A)],

wherein: R^3 represents hydrogen, alkyl, cycloalkyl, $-COR^7$ (wherein R^7 is hydrogen or alkyl), or phenyl optionally substituted with one or two substituents independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkylthio, hydroxy, alkoxy, cyano, nitro, amino, acylamino, monoalkylamino, and
10 dialkylamino, and R^6 is heteroalkyl, heterocyclyl, heterocyclylalkyl, heteroalkylsubstituted heterocyclyl, heteroalkylsubstituted cycloalkyl, heterosubstituted cycloalkyl, $-OR^8$, $-S(O)_nR^8$ (wherein n is an integer from 0 to 2; and R^8 is heteroalkyl, heteroaralkyl, heterocyclyl, or heterocyclylalkyl), $-NR^9R^{10}$ (wherein R^9 is hydrogen or alkyl and R^{10} is heteroalkyl, heteroaralkyl, heterocyclyl, or heterocyclylalkyl), or $-X-(alkylene)-Y-heteroalkyl$ (wherein X is a covalent
15 bond, $-O-$, $-NH-$, or $-S(O)_{n1}-$ where $n1$ is an integer from 0 to 2, and Y is $-O-$, $-NH-$, or $-S-$), or R^6 together with R^4 forms a methylenedioxy or ethylenedioxy group when they are adjacent to each other.

20 Furthermore preferred compounds are:

- (ii) The compound of (i), wherein R^3 is alkyl.
- (iii) The compound of (ii), wherein R^3 is methyl.
- (iv) The compound of (i), wherein R^6 is at the 3-position of the phenyl ring and is heteroalkyl, heterocyclylalkyl, $-OR^8$ (wherein R^8 is heteroalkyl or
25 heterocyclylalkyl), $-NHR^{10}$ (wherein R^{10} is heteroalkyl, heterocyclyl, or heterocyclylalkyl), or $-X-(alkylene)-Y-heteroalkyl$ (wherein X is a covalent bond, $-O-$ or $-NH-$ and Y is $-O-$ or $-NH-$).
- (v) The compound of (iv), wherein R^6 is (*RS*), (*R*) or (*S*) 2,3-dihydroxypropyloxy, 3-hydroxypropyloxy, 2-aminoethyloxy, 3-aminopropyloxy,
30 2-morpholin-4-ylethyloxy, or (*RS*), (*R*) or (*S*) 2,2-dimethyl-1,3-dioxolan-4-ylmethyloxy.

- (vi) The compound of (iv), wherein R^6 is (*RS*), (*R*) or (*S*) 2,3-dihydroxypropylamino, 2-hydroxyethylamino, 3-hydroxypropylamino, (*RS*), (*R*) or (*S*) 2,2-dimethyl-1,3-dioxolan-4-ylmethylamino, 2-hydroxy-1-hydroxymethylethylamino, 3-hydroxybutylamino, or tetrahydropyran-4-ylamino.
- 5 (vii) The compound of (i), wherein R^1 and R^2 are hydrogen; R^4 and R^5 are at the 2 and the 6 positions of the phenyl ring and are independently of each other hydrogen or halogen; and R^6 is at the 3-position of the phenyl ring.
- (viii) The compound of (vii), wherein R^3 is hydrogen or alkyl, R^6 is $-OR^8$ (wherein R^8 is heteroalkyl or heterocyclalkyl), $-NHR^{10}$ (wherein R^{10} is
10 heteroalkyl, heterocycl, or heterocyclalkyl), or $-X-(alkylene)-Y-heteroalkyl$ (wherein X is a covalent bond, $-O-$ or $-NH-$ and Y is $-O-$ or $-NH$).
- (ix) The compound of (viii), wherein R^3 is methyl and R^4 and R^5 are independently of each other hydrogen, chloro, or fluoro.
- (x) The compound of (ix), wherein R^4 and R^5 are hydrogen.
- 15 (xi) The compound of (x), wherein R^6 is (*RS*), (*R*) or (*S*) 2,3-dihydroxypropyloxy, 3-hydroxypropyloxy, 2-aminoethyloxy, 3-aminopropyloxy, 2-morpholin-4-ylethyloxy, or (*RS*), (*R*) or (*S*) 2,2-dimethyl-1,3-dioxolan-4-ylmethyloxy.
- (xii) The compound of (x), wherein R^6 is (*RS*), (*R*) or (*S*) 2,3-dihydroxypropylamino, 2-hydroxyethylamino, 3-hydroxypropylamino, (*RS*), (*R*) or (*S*) 2,2-dimethyl-1,3-dioxolan-4-ylmethylamino, 2-hydroxy-1-hydroxymethylethylamino, 3-hydroxybutylamino, or tetrahydropyran-4-ylamino.
- 20 (xiii) The compound of (i), wherein R^1 is at the 5-position of the indole ring and is halogen; R^2 is hydrogen; R^4 and R^5 are at the 2 and the 6 positions of the phenyl ring and are independently of each other hydrogen or halogen; and R^6 is at the 3-position of the phenyl ring.
- (xiv) The compound of (xiii), wherein R^3 is hydrogen or alkyl, R^6 is $-OR^8$ (wherein R^8 is heteroalkyl or heterocyclalkyl), $-NHR^{10}$ (wherein R^{10} is
25 heteroalkyl, heterocycl, or heterocyclalkyl), or $-X-(alkylene)-Y-heteroalkyl$ (wherein X is a covalent bond, $-O-$ or $-NH-$ and Y is $-O-$ or $-NH$).
- 30 (xv) The compound of (xiv), wherein R^1 is chloro or fluoro; R^3 is methyl; and R^4 and R^5 are independently of each other hydrogen, chloro, or fluoro.

- (xvi) The compound of (xv), wherein R^6 is (RS), (R) or (S) 2,3-dihydroxypropyloxy, 3-hydroxypropyloxy, 2-aminoethyloxy, 3-aminopropyloxy, 2-morpholin-4-ylethyloxy, or (RS), (R) or (S) 2,2-dimethyl-1,3-dioxolan-4-ylmethyloxy.
- 5 (xvii) The compound of (xv), wherein R^6 is (RS), (R) or (S) 2,3-dihydroxypropylamino, 2-hydroxyethylamino, 3-hydroxypropylamino, (RS), (R) or (S) 2,2-dimethyl-1,3-dioxolan-4-ylmethylamino, 2-hydroxy-1-hydroxymethylethylamino, 3-hydroxybutylamino, or tetrahydropyran-4-ylamino.
- (xviii) The compound of (A) or (i) wherein R^6 is at the 2, 3 or 4-position of the
10 phenyl ring.
- (xix) The compound of any one of (A) (i) and (xviii) wherein R^6 is at the 3-position of the phenyl ring.
- (xx) The compound of any one of (A), (i), (xviii) and (xix) wherein R^6 is heteroalkyl, heterocyclalkyl, $-OR^8$ (wherein R^8 is heteroalkyl or
15 heterocyclalkyl), $-NHR^{10}$ (wherein R^{10} is heteroalkyl, heterosubstituted cycloalkyl, heterocycl, or heterocyclalkyl), or $-X-(alkylene)-Y-heteroalkyl$ (wherein X is a covalent bond, $-O-$ or $-NH-$ and Y is $-O-$ or $-NH$).
- (xxi) The compound of any one of (A), (i) and (xviii) to (xx) wherein R^4 and R^5 are at the 2 and the 6 positions of the phenyl ring and are independently of each
20 other hydrogen or halogen.
- (xxii) The compound of any one of (A), (i) and (xviii) to (xxi) wherein R^1 and R^2 are hydrogen.
- (xxiii) The compound of any one of (A), (i) and (xviii) to (xxi) wherein R^1 is at the 5-position of the indole ring and is halogen and R^2 is hydrogen.
- 25 (xxiv) The compound of any one of (A) and (i), (xviii) to (xxiii) wherein R^3 is hydrogen or alkyl, R^6 is $-OR^8$ (wherein R^8 is heteroalkyl or heterocyclalkyl), $-NHR^{10}$ (wherein R^{10} is heteroalkyl, heterosubstituted cycloalkyl, heterocycl, or heterocyclalkyl), or $-X-(alkylene)-Y-heteroalkyl$ (wherein X is a covalent bond, $-O-$ or $-NH-$ and Y is $-O-$ or $-NH$).
- 30 (xxv) The compound of any one of (A), (i) and (xviii) to (xxiv) wherein R^3 is hydrogen or alkyl, R^6 is $-OR^8$ (wherein R^8 is heteroalkyl or heterocyclalkyl), $-NHR^{10}$ (wherein R^{10} is heteroalkyl, heterocycl, or heterocyclalkyl), or $-X-$

(alkylene)-Y-heteroalkyl (wherein X is a covalent bond, -O- or -NH- and Y is -O- or -NH).

(xxvi) The compound of any one of (A), (i) and (xviii) to (xxv) wherein R³ is alkyl.

5 (xxvii) The compound of any one of (A), (i) and (xviii) to (xxvi) wherein R³ is methyl.

(xxviii) The compound of any one of (A), (i) and (xviii) to (xxvii) wherein R⁴ and R⁵ are independently of each other hydrogen, chloro, or fluoro.

10 (xxix) The compound of any one of (A), (i) and (xviii) to (xxviii) wherein R⁴ and R⁵ are hydrogen.

(xxx) The compound of any one of (A), (i) and (xviii) to (xxix) wherein R⁶ is (RS), (R) or (S) 2,3-dihydroxypropylloxy, 3-hydroxypropyloxy, 2-aminoethyloxy, 3-aminopropyloxy, 2-morpholin-4-ylethyloxy, or (RS), (R) or (S) 2,2-dimethyl-1,3-dioxolan-4-ylmethyloxy.

15 (xxxi) The compound of any one of (A), (i) and (xviii) to (xxix) wherein R⁶ is (RS), (R) or (S) 2,3-dihydroxypropylamino, 2-hydroxyethylamino, 3-hydroxypropylamino, (RS), (R) or (S) 2,2-dimethyl-1,3-dioxolan-4-ylmethylamino, 2-hydroxy-1-hydroxymethylethylamino, 3-hydroxybutylamino, or tetrahydropyran-4-ylamino.

20

The compounds of the present invention exhibit surprisingly effective activity against GSK-3 β . It is contemplated that the improved activity is due to their enhanced bioavailability and increased metabolic stability.

25

In a second aspect, this invention is directed to a medicament comprising a therapeutically effective amount of a compound of formula (I) and a pharmaceutically acceptable excipient. In particular, the aforementioned medicament is useful for the treatment of GSK-3 β mediated diseases selected from Alzheimer's disease, obesity, diabetes, atherosclerotic cardiovascular disease, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency, cancer, allergy, and asthma in a mammal, and especially useful for the treatment of asthma.

30

In a third aspect, this invention provides processes for preparing compounds of Formula I.

In a fourth aspect, this invention is directed to the use of a compound of formula I for the manufacture of medicaments comprising one or more compounds of formula I for the treatment of GSK-3 β mediated diseases selected from Alzheimer's disease, obesity, diabetes, atherosclerotic cardiovascular disease, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency, cancer, allergy, and asthma in a mammal, especially, asthma.

In a fifth aspect, this invention is directed to the use of an inhibitor of GSK-3 β for the treatment of a disease characterized by an excess of CD4+ Th2 cytokines, such as asthma, allergy or allergic rhinitis, especially asthma.

In a sixth aspect, this invention is directed to the use of an inhibitor of GSK-3 β for the treatment of a disease characterized by an excess IgE production such as asthma, allergy or allergic rhinitis, especially asthma.

Figure 1 shows the correlation between GSK inhibition by compounds of the invention and β -catenin levels in Jurkat T-cells.

Figure 2A shows expression of TCF7 transcripts in mRNA from the B10.D2 cells relative to that in Balb/C T-cells.

Figure 2B shows the induction of TCF-7 by interferon-gamma.

Unless otherwise stated, the following terms used in the specification and claims have the meanings given below:

"Alkyl" means a linear saturated monovalent hydrocarbon radical of one to six carbon atoms or a branched saturated monovalent hydrocarbon radical of three to six carbon atoms, e.g., methyl, ethyl, propyl, 2-propyl, *n*-butyl, *iso*-butyl, *tert*-butyl, pentyl, and the like.

"Alkylene" means a linear saturated divalent hydrocarbon radical of one to six carbon atoms or a branched saturated divalent hydrocarbon radical of three to six carbon atoms, e.g., methylene, ethylene, 2,2-dimethylethylene, propylene, 2-methylpropylene, butylene, pentylene, and the like.

5

"Alkoxy" means a radical -OR where R is an alkyl as defined above e.g., methoxy, ethoxy, propoxy, butoxy and the like.

10

"Alkylthio" means a radical -SR where R is an alkyl as defined above e.g., methylthio, ethylthio, propylthio, butylthio, and the like.

15

"Acyl" means a radical -C(O)R, where R is hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, phenyl or phenylalkyl wherein alkyl, cycloalkyl, cycloalkylalkyl, and phenylalkyl are as defined herein. Representative examples include, but are not limited to formyl, acetyl, cyclohexylcarbonyl, cyclohexylmethylcarbonyl, benzoyl, benzylcarbonyl, and the like.

20

"Acylamino" means a radical -NR'C(O)R, where R' is hydrogen or alkyl, and R is hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, phenyl or phenylalkyl wherein alkyl, cycloalkyl, cycloalkylalkyl, and phenylalkyl are as defined herein. Representative examples include, but are not limited to formylamino, acetylamino, cyclohexylcarbonylamino, cyclohexylmethyl-carbonylamino, benzoylamino, benzylcarbonylamino, and the like.

25

"Cycloalkyl" refers to a saturated monovalent cyclic hydrocarbon radical of three to seven ring carbons e.g., cyclopropyl, cyclobutyl, cyclohexyl, 4-methylcyclohexyl, and the like.

30

"Cycloalkylalkyl" means a radical -R^aR^b where R^a is an alkylene group as defined herein and R^b is a cycloalkyl group as defined herein, e.g., cyclohexylmethyl, and the like.

"Dialkylamino" means a radical -NRR' where R and R' independently represent an alkyl, cycloalkyl, or cycloalkylalkyl group as defined herein. Representative examples include, but are not limited to dimethylamino, methylethylamino, di(1-methylethyl)amino, (cyclohexyl)(methyl)amino, (cyclohexyl)(ethyl)amino, (cyclohexyl)(propyl)amino, (cyclohexylmethyl)(methyl)amino, (cyclohexylmethyl)(ethyl)amino, and the like.

"Halogen" means fluoro, chloro, bromo, or iodo, preferably fluoro or chloro.

"Haloalkyl" means alkyl substituted with one or more same or different halogen atoms, e.g., -CH₂Cl, -CF₃, -CH₂CF₃, -CH₂CCl₃, and the like.

"Heteroalkyl" means an alkyl radical as defined herein wherein one, two or three hydrogen atoms have been replaced with a substituent independently selected from the group consisting of -OR^a, -NR^bR^c, and -S(O)_nR^d (where n is an integer from 0 to 2), with the understanding that the point of attachment of the heteroalkyl radical is through a carbon atom, wherein R^a is hydrogen, acyl, alkyl, cycloalkyl, or cycloalkylalkyl; R^b and R^c are independently of each other hydrogen, acyl, alkyl, cycloalkyl, or cycloalkylalkyl; and when n is 0, R^d is hydrogen, alkyl, cycloalkyl, or cycloalkylalkyl, and when n is 1 or 2, R^d is alkyl, cycloalkyl, cycloalkylalkyl, amino, acylamino, monoalkylamino, or dialkylamino. Representative examples include, but are not limited to, 2-hydroxyethyl, 3-hydroxypropyl, 3-hydroxy-1-methylpropyl, 2-hydroxy-1-hydroxymethylethyl, 2,3-dihydroxypropyl, 1-hydroxymethylethyl, 3-hydroxybutyl, 2,3-dihydroxybutyl, 2-hydroxy-1-methylpropyl, 2-aminoethyl, 3-aminopropyl, 2-methylsulfonylethyl, amino-sulfonylmethyl, aminosulfonylethyl, aminosulfonylpropyl, methylamino-sulfonylmethyl, methylaminosulfonylethyl, methylaminosulfonylpropyl, and the like.

30

"Hydroxyalkyl" means an alkyl radical as defined herein, substituted with one or more, preferably one, two or three hydroxy groups, provided that the same

carbon atom does not carry more than one hydroxy group. Representative examples include, but are not limited to, 2-hydroxyethyl, 2-hydroxypropyl, 3-hydroxypropyl, 1-(hydroxymethyl)-2-methylpropyl, 2-hydroxybutyl, 3-hydroxybutyl, 4-hydroxybutyl, 2,3-dihydroxypropyl, 2-hydroxy-1-hydroxymethylethyl, 2,3-dihydroxybutyl, 3,4-dihydroxybutyl and 2-(hydroxymethyl)-3-hydroxypropyl, preferably 2-hydroxyethyl, 2,3-dihydroxypropyl and 1-(hydroxymethyl)-2-hydroxyethyl. Accordingly, as used herein, the term "hydroxyalkyl" is used to define a subset of heteroalkyl groups.

"Heterosubstituted cycloalkyl" means a cycloalkyl radical as defined herein wherein one, two or three hydrogen atoms in the cycloalkyl radical have been replaced with a substituent independently selected from the group consisting of hydroxy, alkoxy, amino, acylamino, monoalkylamino, dialkylamino, or $-S(O)_nR$ (where n is an integer from 0 to 2) such that when n is 0, R is hydrogen, alkyl, cycloalkyl, or cycloalkylalkyl, and when n is 1 or 2, R is alkyl, cycloalkyl, cycloalkylalkyl, amino, acylamino, monoalkylamino, or dialkylamino. Representative examples include, but are not limited to, 2-, 3-, or 4-hydroxycyclohexyl, 2-, 3-, or 4-aminocyclohexyl, 2-, 3-, or 4-sulfonamidocyclohexyl, and the like, preferably 4-hydroxycyclohexyl, 2-aminocyclohexyl, 4-sulfonamidocyclohexyl.

"Heteroalkylsubstituted cycloalkyl" means a cycloalkyl radical as defined herein wherein one, two or three hydrogen atoms in the cycloalkyl radical have been replaced with a heteroalkyl group as defined herein with the understanding that the heteroalkyl radical is attached to the cycloalkyl radical via a carbon-carbon bond. Representative examples include, but are not limited to, 1-hydroxymethylcyclopentyl, 2-hydroxymethylcyclohexyl, and the like.

"Heteroaryl" means a monovalent monocyclic or bicyclic radical of 5 to 12 ring atoms having at least one aromatic ring containing one, two, or three ring heteroatoms selected from N, O, or S, the remaining ring atoms being C, with the understanding that the attachment point of the heteroaryl radical will be on an

aromatic ring. The heteroaryl ring is optionally substituted independently with one or more substituents, preferably one or two substituents, selected from alkyl, haloalkyl, heteroalkyl, hydroxy, alkoxy, halogen, nitro, cyano. More specifically the term heteroaryl includes, but is not limited to, pyridyl, furanyl, thienyl, thiazolyl, isothiazolyl, triazolyl, imidazolyl, isoxazolyl, pyrrolyl, pyrazolyl, pyrimidinyl, benzofuranyl, tetrahydrobenzofuranyl, isobenzofuranyl, benzothiazolyl, benzoisothiazolyl, benzotriazolyl, indolyl, isoindolyl, benzoxazolyl, quinolyl, tetrahydroquinolyl, isoquinolyl, benzimidazolyl, benzisoxazolyl or benzothieryl, and the derivatives thereof.

"Heteroalkyl" means a radical $-R^aR^b$ where R^a is an alkylene group as defined herein and R^b is a heteroaryl group as defined herein, *e.g.*, pyridin-3-ylmethyl, imidazolylmethyl, imidazolylethyl, pyridinylethyl, 3-(benzofuran-2-yl)propyl, and the like.

"Heterocyclyl" means a saturated cyclic radical of 5 to 8 ring atoms in which one or two ring atoms are heteroatoms selected from NR (where R is independently hydrogen, alkyl, or heteroalkyl), O, or $S(O)_n$ (where n is an integer from 0 to 2), the remaining ring atoms being C, where one or two C atoms may optionally be replaced by a carbonyl group. The heterocyclyl ring may be optionally substituted independently with one, two, or three substituents selected from alkyl, haloalkyl, heteroalkyl, halogen, nitro, cyano, hydroxy, alkoxy, amino, monoalkylamino, dialkylamino, -COR (where R is alkyl). More specifically the term heterocyclyl includes, but is not limited to, tetrahydropyranyl, 2,2-dimethyl-1,3-dioxolane, 2,2-dimethyl-1,3-dioxane-5-yl, piperidino, N-methylpiperidin-3-yl, piperazino, N-methylpyrrolidin-3-yl, 3-pyrrolidino, morpholin-4-yl, morpholino, thiomorpholino, thiomorpholino-1-oxide, thiomorpholino-1,1-dioxide, pyrrolinyl, imidazolyl, and the derivatives thereof.

"Heteroalkylsubstituted heterocyclyl" means a heterocyclyl radical as defined herein wherein one, two or three hydrogen atoms in the heterocyclyl radical have been replaced with a heteroalkyl group with the understanding that the

heteroalkyl radical is attached to the heterocyclyl radical via a carbon-carbon bond. Representative examples include, but are not limited to, 4-hydroxymethylpiperidin-1-yl, 4-hydroxymethylpiperazin-1-yl, 4-hydroxyethylpiperidin-1-yl, 4-hydroxyethylpiperazin-1-yl, and the like.

5

"Heterocyclylalkyl" means a radical $-R^aR^b$ where R^a is an alkylene group as defined herein and R^b is a heterocyclyl group as defined herein, *e.g.*, tetrahydropyran-2-ylmethyl, 4-methylpiperazin-1-ylethyl, 3-piperidinylmethyl, 2,2-dimethyl-1,3-dioxoxolan-4-ylmethyl, benzyl, cyclohexylmethyl, 2-morpholin-4-ylethyl, and the like.

10

"Monoalkylamino" means a radical $-NHR$ where R is an alkyl, cycloalkyl, or cycloalkylalkyl group as defined above, *e.g.*, methylamino, (1-methylethyl)amino, cyclohexylamino, cyclohexylmethylamino, cyclohexylethylamino, 2-morpholin-4-ylethyl and the like.

15

"Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. For example, "heterocyclo group optionally mono- or di- substituted with an alkyl group" means that the alkyl may but need not be present, and the description includes situations where the heterocyclo group is mono- or disubstituted with an alkyl group and situations where the heterocyclo group is not substituted with the alkyl group.

20

25

"Phenylalkyl" means a radical $-R^aR^b$ where R^a is an alkylene group and R^b is a phenyl group as defined herein, *e.g.*, benzyl and the like.

30

"Hydroxy or amino protecting group" refers to those organic groups intended to protect oxygen and nitrogen atoms against undesirable reactions during synthetic procedures. Suitable oxygen and nitrogen protecting groups are well known in the art *e.g.*, trimethylsilyl, dimethyl-*tert*-butylsilyl, benzyl, benzyloxy-

carbonyl (CBZ), *tert*-butoxycarbonyl (Boc), trifluoroacetyl, 2-trimethylsilylethanesulfonyl (SES), and the like. Others can be found in the book by T. W. Greene and G. M. Wuts, *Protecting Groups in Organic Synthesis*, Second Edition, Wiley, New York, 1991, and references cited therein..

5

Compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed "isomers". Isomers that differ in the arrangement of their atoms in space are termed "stereoisomers". Stereoisomers that are not mirror images of one another are termed "diastereomers" and those that are non-superimposable mirror images of each other are termed "enantiomers". When a compound has an asymmetric center, for example, it is bonded to four different groups, a pair of enantiomers is possible. An enantiomer can be characterized by the absolute configuration of its asymmetric center and is described by the R- and S-sequencing rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory (i.e., as (+) or (-)-isomers respectively). A chiral compound can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a "racemic mixture".

20

The compounds of this invention may possess one or more asymmetric centers; such compounds can therefore be produced as individual (R)- or (S)-stereoisomers or as mixtures thereof. For example, if the R⁶ substituent in a compound of formula (I) is 2-hydroxyethyl, then the carbon to which the hydroxy group is attached is an asymmetric center and therefore the compound of Formula (I) can exist as an (R)- or (S)-stereoisomer. Unless indicated otherwise, the description or naming of a particular compound in the specification and claims is intended to include both individual enantiomers and mixtures, racemic or otherwise, thereof. The methods for the determination of stereochemistry and the separation of stereoisomers are well-known in the art (*see* discussion in Chapter 4 of "Advanced Organic Chemistry", 4th edition J. March, John Wiley and Sons, New York, 1992).

30

A "pharmaceutically acceptable excipient" means an excipient that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes an excipient that is acceptable for veterinary use as well as human pharmaceutical use. A
5 "pharmaceutically acceptable excipient" as used in the specification and claims includes both one and more than one such excipient.

A "pharmaceutically acceptable salt" of a compound means a salt that is pharmaceutically acceptable and that possesses the desired pharmacological
10 activity of the parent compound. Such salts include:

(1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid,
15 cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid,
20 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynapthoic acid, salicylic acid, stearic acid, muconic acid, and the like; or

(2) salts formed when an acidic proton present in the parent compound
25 either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, and the like.

A compound of Formula (I) may act as a pro-drug. Prodrug means any
30 compound which releases an active parent drug according to Formula (I) *in vivo* when such prodrug is administered to a mammalian subject. Prodrugs of a compound of Formula (I) are prepared by modifying functional groups present in


the compound of Formula (I) in such a way that the modifications may be cleaved *in vivo* to release the parent compound. Prodrugs include compounds of Formula (I) wherein a hydroxy, amino, or sulfhydryl group in compound (I) is bonded to any group that may be cleaved *in vivo* to regenerate the free hydroxyl, amino, or sulfhydryl group, respectively. Examples of prodrugs include, but are not limited to esters (e.g., acetate, formate, and benzoate derivatives), carbamates (e.g., N,N-dimethylamino-carbonyl) of hydroxy functional groups in compounds of Formula (I), and the like.

"Treating" or "treatment" of a disease includes:

- (1) preventing the disease, i.e. causing the clinical symptoms of the disease not to develop in a mammal that may be exposed to or predisposed to the disease but does not yet experience or display symptoms of the disease,
- (2) inhibiting the disease, i.e., arresting or reducing the development of the disease or its clinical symptoms, or
- (3) relieving the disease, i.e., causing regression of the disease or its clinical symptoms.

A "therapeutically effective amount" means the amount of a compound that, when administered to a mammal for treating a disease, is sufficient to effect such treatment for the disease. The "therapeutically effective amount" will vary depending on the compound, the disease and its severity and the age, weight, etc., of the mammal to be treated.

The naming and numbering of the compounds of this invention is illustrated



below.


The nomenclature used in this application is generally based on the IUPAC recommendations. Since strict adherence to these recommendations would result in the names changing substantially when only a single substituent is changes, compounds have been named in a form that maintains consistency of nomenclature for the basic structure of the molecule. For example,

a compound of Formula (I) where R^1 , R^2 , R^4 and R^5 are hydrogen, R^3 is methyl, R^6 is 2-hydroxyethylamino and is meta to the carbon attaching the phenyl ring to the pyrrole-2,5-dione ring is named 3-(1-methylindolyl)-4-[3-(2-hydroxyethylaminophenyl)-1H-pyrrole-2,5-dione].

a compound of Formula (I) where R^1 , R^2 , R^4 and R^5 are hydrogen, R^3 is methyl, R^6 is 2-hydroxyethylamino and is para to the carbon attaching the phenyl ring to the pyrrole-2,5-dione ring is named 3-(1-methylindolyl)-4-[4-(2-hydroxyethylaminophenyl)-1H-pyrrole-2,5-dione].


Representative compounds of this invention are as follows

I. Compounds of Formula (I) where R^1 , R^2 , R^4 and R^5 = hydrogen, R^3 = methyl, and R^6 is as defined below are:



Cpd. #	R^6	M. pt °C	Mass Spec.	Example
I-1	2,3-dihydroxypropyloxy	245-247.1	392 M^+	1
I-2	2,2-dimethyl-1,3-dioxolan-4-ylmethoxy	220.8-221.2	432 M^+	2

- II. Compounds of Formula (I) where R^1, R^2, R^4 and R^5 = hydrogen, R^3 = methyl, and R^6 is as defined below are:




Cpd. #	R^6	M. pt °C	Mass Spec.	Example
II-1	2-aminoethoxy ^(*)	182.4-187	362 M ⁺	6
II-2	3-aminopropoxy ^(*)		375 M ⁺	5
II-3	2(R),3-dihydroxypropoxy	177.7-178	392 M ⁺	2
II-4	2-morpholin-4-ylethoxy	197.7-199	431 M ⁺	3
II-5	2(S),3-dihydroxy-propoxy	176.9-178.1	392 M ⁺	2
II-6	(R)-2,2-dimethyl-1,3-dioxolan-4-ylmethoxy		432 M ⁺	1
II-7	(S)-2,2-dimethyl-1,3-dioxolan-4-ylmethoxy	186.8-187.4	432 M ⁺	1
II-8	(RS)-2,2-dimethyl-1,3-dioxolan-4-yl-methylamino		431 M ⁺	7
II-9	2,3-dihydroxy-propylamino	160-163.5	392 (M+H) ⁺	7
II-10	2,2-dimethyl-1,3-dioxan-5-ylamino	201-203	431 M ⁺	9
II-11	(RS)-2-hydroxy-1-hydroxymethylethylamino	97.5-101	391 M ⁺	10
II-12	(RS)-3-hydroxybutylamino		389 M ⁺	14
II-13	(RS)-2-hydroxy-1-methylpropylamino		389 M ⁺	15
II-13A	tetrahydropyran-4-ylamino		401 M ⁺	8
II-14	imidazol-2-ylmethylamino		397 M ⁺	11

Cpd. #	R ⁶	M. pt °C	Mass Spec.	Example
II-15	morpholin-4-yl ^(*)	205.3-212.6	388 M ⁺	4
II-16	3-(<i>tert</i> -butyl-dimethylsilyl-oxy)propylamino	58-65	490 (M+H) ⁺	12
II-17	2-(<i>tert</i> -butyl-diphenylsilyl-oxy)ethylamino		600 (M+H) ⁺	12
II-18	3-hydroxypropylamino ^(*)	180-192	376 (M+H) ⁺	13
II-19	2-hydroxyethylamino ^(*)	170.3-170.6	362 (M+H) ⁺	13
II-20	3-hydroxypropyloxy	150.2-152.6	377 (M+H) ⁺	13
II-21	3-(<i>tert</i> -butyl-dimethylsilyl-oxy)propyloxy	151.2-151.7	491 (M+H) ⁺	6
II-22	(<i>RS</i>)-1-hydroxymethylethylamino	203.1-205.8	376 (M+H) ⁺	15
II-23	3-hydroxy-1-methylpropylamino		389 M ⁺	14
II-24	(<i>RS</i>)-bis(2,3-dihydroxypropyl)amino		466 (M+H) ⁺	7
II-25	pyrrolidin-1-yl		372 M ⁺	4
II-26	(<i>S</i>)-2,3-dihydroxypropylamino		392 (M+H) ⁺	7
II-27	2(<i>R</i>),3-dihydroxypropylamino ^(*)		392 (M+H) ⁺	7
II-28	4-hydroxycyclohexylamino		415 M ⁺	8
II-29	4-hydroxypiperidin-1-yl	136.0-141.0	402 (M+H) ⁺	23
II-30	(<i>R</i>)-2,2-dimethyl-1,3-dioxolan-4-yl-methylsulfanyl		448 M ⁺	18
II-31	(<i>R</i>)-2,3-dihydroxypropylsulfanyl		408 M ⁺	21
II-32	(<i>R</i>)-2,2-dimethyl-1,3-dioxolan-4-yl-methylsulfinyl		465 (M+H) ⁺	19

Cpd. #	R ⁶	M. pt °C	Mass Spec.	Example
II-33	(R)-2,3-dihydroxypropylsulfinyl		425 (M+H) ⁺	21
II-34	(R)-2,2-dimethyl-1,3-dioxolan-4-yl-methylsulfonyl		481 (M+H) ⁺	20
II-35	(R)-2,3-dihydroxypropylsulfonyl		411 (M+H) ⁺	21

(*) means hydrochloride

III. Compounds of Formula (I) where R², R⁴ and R⁵ = hydrogen, R¹, R³ and R⁶ are as defined below are:




Cpd. #	R ¹	R ³	R ⁶	M. pt °C	Mass Spec.	Example
III-1	chloro	methyl	(RS)-2,3-dihydroxypropylamino	224.5-225.7	426 (M+H) ⁺	16
III-2	fluoro	methyl	3-aminopropoxy(*)	223.2-225.0	410 (M+H) ⁺	17
III-3	H	H	2-morpholin-4-yl-ethoxy		417 (M+H) ⁺	3
III-4	chloro	methyl	(R)-2,3-dihydroxypropyloxy		427 (M+H) ⁺	24
III-5	fluoro	methyl	(R)-2,3-dihydroxypropyloxy		411 (M+H) ⁺	24
III-6	fluoro	3-hydroxy-propyl	(RS)-2,3-dihydroxy-propylamino		454 (M+H) ⁺	22
III-7	methoxy	methyl	2,3-dihydroxy-propylamino		421	25
III-8	methyl	methyl	2,3-dihydroxy-propylamino		405	25

Cpd. #	R ¹	R ³	R ⁶	M. pt °C	Mass Spec.	Example
III-9	isopropoxy	methyl	2,3-dihydroxy-propylamino		449	26

(*) means hydrochloride

IV. Compounds of Formula (I) where R¹, R², R⁴ and R⁵ = hydrogen, R³ = methyl, and R⁶ is as defined below are:



5

Cpd. #	R ⁶	m. pt °C	Mass Spec.	Example
IV-1	(R)-2,2-dimethyl-1,3-dioxolan-4-yl-methyloxy		432 M ⁺	1
IV-2	(RS)-2,3-dihydroxy-propylamino	212-213.5		7
IV-3	(RS)-2,2-dimethyl-1,3-dioxolan-4-yl-methylamino	85-87.8		7
IV-4	3-hydroxybutylamino	58-61.5	389 M ⁺	13
IV-5	(RS)-1-methyl-2-hydroxyethylamino		375	15
IV-6	2(R),3-dihydroxypropyloxy	220.3-222.7	392 M ⁺	1

V. Additional compounds of Formula (I) where only one of R⁴-R⁶ is hydrogen are:

10

3-(1-methyl-indol-3-yl)-4-{3-((R)-2,3-dihydroxy-propoxyl)-2-methylphenyl}-1H-pyrrole-2,5-dione (Example 27);

3-(1-methyl-indol-3-yl)-4-{3-((R)-2,3-dihydroxy-propoxyl)-2-nitrophenyl}-1H-pyrrole-2,5-dione (Example 28); and
3-(1-methylindol-3-yl)-4-[5-((R)-2,3-dihydroxypropoxy)-2-nitrophenyl]-1H-pyrrole-2,5-dione (Example 28).

5

While the broadest definition of this invention is set forth in the Summary of the Invention, certain compounds of Formula (I) are preferred.

10

(A) A preferred group of compounds is that wherein R^3 is alkyl, preferably methyl or ethyl, more preferably methyl.

15

Within this group a more preferred group of compounds is that wherein R^6 is at the 3- or 5-position of the phenyl ring, preferably R^6 is at the 3- position of the phenyl ring.

20

Within this group a more preferred group of compounds is that wherein R^6 is heteroalkyl.

Another more preferred group of compounds is that wherein R^6 is heterocyclalkyl.

25

Yet another more preferred group of compounds is that wherein R^6 is $-OR^8$ (wherein R^8 is heteroalkyl or heterocyclalkyl), preferably (RS), (R) or (S)-2,3-dihydroxypropyloxy, 3-hydroxypropyloxy, 2-aminoethyloxy, 3-aminopropyloxy, 2-morpholin-4-ylethyloxy, or (R) or (S)-2,2-dimethyl-1,3-dioxolan-4-ylmethyloxy, more preferably (RS), (R) or (S)-2,3-dihydroxypropyloxy.

30

Yet another more preferred group of compounds is that wherein R^6 is $-NHR^{10}$ (wherein R^{10} is heteroalkyl, heterocycl, or heterocyclalkyl), preferably (RS), (R) or (S)-2,3-dihydroxypropylamino, 2-hydroxyethylamino, 3-hydroxypropylamino, (RS), (R) or (S)-2,2-dimethyl-1,3-dioxolan-4-ylmethylamino, 2,2-dimethyl-1,3-dioxan-5-ylamino, 2-hydroxy-1-hydroxymethylethylamino, 3-

hydroxybutylamino, imidazol-2-ylmethylamino, or tetrahydropyran-4-ylamino, more preferably (*RS*), (*R*) or (*S*)-2,3-dihydroxypropylamino, (*RS*), (*R*) or (*S*)-2,2-dimethyl-1,3-dioxolan-4-ylmethylamino, 3-hydroxybutylamino, or 2-hydroxy-1-hydroxymethyl-ethylamino.

5

Yet another more preferred group of compounds is that wherein R^6 is heterocyclyl or -X-(alkylene)-Y-heteroalkyl (wherein X is a covalent bond, -O- or -NH- and Y is -O- or -NH-), preferably heterocyclyl, more preferably morpholin-4-yl or pyrrolidin-1-yl.

10

Yet another more preferred group of compounds is that wherein R^6 is -S(O) $_n$ R⁸ (wherein n is an integer from 0 to 2; and R⁸ is heteroalkyl, heteroaralkyl, heterocyclyl, or heterocyclalkyl), preferably R^6 is -S(O) $_n$ R⁸ (wherein n is an integer from 0 to 2; and R⁸ is heteroalkyl or heterocyclalkyl), more preferably R^6 is (*RS*), (*R*) or (*S*)-2,2-dimethyl-1,3-dioxolan-4-ylmethyl sulfanyl, (*RS*), (*R*) or (*S*)-2,3-dihydroxypropylsulfanyl, (*RS*), (*R*) or (*S*)-2,2-dimethyl-1,3-dioxolan-4-ylmethyl sulfinyl, (*RS*), (*R*) or (*S*)-2,3-dihydroxypropylsulfinyl, (*RS*), (*R*) or (*S*)-2,2-dimethyl-1,3-dioxolan-4-ylmethyl sulfonyl, or (*RS*), (*R*) or (*S*)-2,3-dihydroxypropylsulfonyl.

15

20

Yet another more preferred group of compounds is that wherein R^6 is heterosubstituted cyclohexylamino.

25

Within these preferred and more preferred groups of compounds, an even more preferred group of compounds is that wherein:

R^1 and R^2 are hydrogen; or R^1 is halogen, preferably chloro and is located at the 5-position of the indole ring and R^2 is hydrogen; and

30

R^4 and R^5 are at the 2- and the 6- positions of the phenyl ring respectively and are hydrogen, alkyl, halogen, alkoxy, cyano or nitro, preferably hydrogen, chloro or fluoro, more preferably R^4 and R^5 are both hydrogen or one of R^4 and R^5 is fluoro and the other is hydrogen, or both of R^4 and R^5 are fluoro.

(B) Another preferred group of compounds is that wherein R^6 is at the 3- or 5-position of the phenyl ring, preferably R^6 is at the 3- position of the phenyl ring.

5 Within this group a more preferred group of compounds is that wherein R^6 is heteroalkyl.

Another more preferred group of compounds is that wherein R^6 is heterocyclalkyl.

10 Yet another more preferred group of compounds is that wherein R^6 is $-OR^8$ (wherein R^8 is heteroalkyl or heterocyclalkyl), preferably (*RS*), (*R*) or (*S*)-2,3-dihydroxypropyloxy, 3-hydroxypropyloxy, 2-aminoethyloxy, 3-aminopropyloxy, 2-morpholin-4-ylethyloxy, or (*R*) or (*S*)-2,2-dimethyl-1,3-dioxolan-4-ylmethyloxy, more preferably (*RS*), (*R*) or (*S*)-2,3-dihydroxypropyloxy.

15 Yet another more preferred group of compounds is that wherein R^6 is $-NHR^{10}$ (wherein R^{10} is heteroalkyl, heterocycl, or heterocyclalkyl), preferably (*RS*), (*R*) or (*S*)-2,3-dihydroxypropylamino, 2-hydroxyethylamino, 3-hydroxypropylamino, (*RS*), (*R*) or (*S*)-2,2-dimethyl-1,3-dioxolan-4-ylmethylamino, 2,2-dimethyl-1,3-dioxan-5-ylamino, 2-hydroxy-1-hydroxymethylethylamino, 3-hydroxybutylamino, imidazol-2-ylmethylamino, or tetrahydropyran-4-ylamino, more preferably (*RS*), (*R*) or (*S*)-2,3-dihydroxypropylamino, (*RS*), (*R*) or (*S*)-2,2-dimethyl-1,3-dioxolan-4-ylmethylamino, 3-hydroxybutylamino, or 2-hydroxy-1-hydroxymethylethylamino.

25 Yet another more preferred group of compounds is that wherein R^6 is heterocycl or $-X-(alkylene)-Y$ -heteroalkyl (wherein X is a covalent bond, $-O-$ or $-NH-$ and Y is $-O-$ or $-NH-$), preferably heterocycl, more preferably morpholin-4-yl or pyrrolidin-1-yl.

30 Yet another more preferred group of compounds is that wherein R^6 is $-S(O)_nR^8$ (wherein n is an integer from 0 to 2; and R^8 is heteroalkyl, heteroaralkyl,

heterocyclyl, or heterocyclylalkyl), preferably R^6 is $-S(O)_nR^8$ (wherein n is an integer from 0 to 2; and R^8 is heteroalkyl or heterocyclylalkyl), more preferably R^6 is (*RS*), (*R*) or (*S*)-2,2-dimethyl-1,3-dioxolan-4-ylmethyl sulfanyl, (*RS*), (*R*) or (*S*)-2,3-dihydroxypropylsulfanyl, (*RS*), (*R*) or (*S*)-2,2-dimethyl-1,3-dioxolan-4-ylmethyl sulfinyl, (*RS*), (*R*) or (*S*)-2,3-dihydroxypropylsulfinyl, (*RS*), (*R*) or (*S*)-2,2-dimethyl-1,3-dioxolan-4-ylmethyl sulfonyl, or (*RS*), (*R*) or (*S*)-2,3-dihydroxypropylsulfonyl.

Yet another more preferred group of compounds is that wherein R^6 is heterosubstituted cyclohexylamino.

Within these preferred and more preferred groups of compounds, an even more preferred group of compounds is that wherein R^3 is alkyl, preferably ethyl or methyl; more preferably methyl.

Within these preferred, more preferred, and even more preferred groups of compounds, a particularly preferred group of compounds is that wherein:

R^1 and R^2 are hydrogen; or R^1 is halogen, preferably chloro and is located at the 5-position of the indole ring and R^2 is hydrogen; and

R^4 and R^5 are at the 2- and the 6- positions of the phenyl ring respectively and are hydrogen, alkyl, halogen, alkoxy, cyano or nitro, preferably hydrogen, chloro or fluoro, more preferably R^4 and R^5 are both hydrogen, or one of R^4 and R^5 is fluoro and the other is hydrogen, or both of R^4 and R^5 are fluoro.

(C) Yet another preferred group of compounds is that wherein R^1 and R^2 are at the 5- and 7-positions of the indole ring respectively; R^4 and R^5 are at the 2- and the 6-positions of the phenyl ring respectively and R^6 is at the 3- or 5-position of the phenyl ring, preferably R^6 is at the 3- position of the phenyl ring.

Within this group a more preferred group of compounds is that wherein R^6 is heteroalkyl.

Another more preferred group of compounds is that wherein R^6 is heterocyclalkyl.

Yet another more preferred group of compounds is that wherein R^6 is $-OR^8$ (wherein R^8 is heteroalkyl or heterocyclalkyl), preferably (*RS*), (*R*) or (*S*)-2,3-dihydroxypropyloxy, 3-hydroxypropyloxy, 2-aminoethyloxy, 3-aminopropyloxy, 2-morpholin-4-ylethyloxy; or (*R*) or (*S*)-2,2-dimethyl-1,3-dioxolan-4-ylmethyloxy, more preferably (*RS*), (*R*) or (*S*)-2,3-dihydroxypropyloxy.

Yet another more preferred group of compounds is that wherein R^6 is $-NHR^{10}$ (wherein R^{10} is heteroalkyl, heterocycl, or heterocyclalkyl), preferably (*RS*), (*R*) or (*S*)-2,3-dihydroxypropylamino, 2-hydroxyethylamino, 3-hydroxypropylamino, (*RS*), (*R*) or (*S*)-2,2-dimethyl-1,3-dioxolan-4-ylmethylamino, 2,2-dimethyl-1,3-dioxan-5-ylamino, 2-hydroxy-1-hydroxymethylethylamino, 3-hydroxybutylamino, imidazol-2-ylmethylamino, or tetrahydropyran-4-ylamino, more preferably (*RS*), (*R*) or (*S*)-2,3-dihydroxypropylamino, (*RS*), (*R*) or (*S*)-2,2-dimethyl-1,3-dioxolan-4-ylmethylamino, 3-hydroxybutylamino, or 2-hydroxy-1-hydroxymethyl-ethylamino.

Yet another more preferred group of compounds is that wherein R^6 is heterocycl or $-X-(alkylene)-Y$ -heteroalkyl (wherein X is a covalent bond, $-O-$ or $-NH-$ and Y is $-O-$ or $-NH-$), preferably heterocycl, more preferably morpholin-4-yl or pyrrolidin-1-yl.

Yet another more preferred group of compounds is that wherein R^6 is $-S(O)_nR^8$ (wherein n is an integer from 0 to 2; and R^8 is heteroalkyl, heteroalkyl, heterocycl, or heterocyclalkyl), preferably R^6 is $-S(O)_nR^8$ (wherein n is an integer from 0 to 2; and R^8 is heteroalkyl or heterocyclalkyl), more preferably R^6 is (*RS*), (*R*) or (*S*)-2,2-dimethyl-1,3-dioxolan-4-ylmethyl sulfanyl, (*RS*), (*R*) or (*S*)-2,3-dihydroxypropylsulfanyl, (*RS*), (*R*) or (*S*)-2,2-dimethyl-1,3-dioxolan-4-ylmethyl sulfinyl, (*RS*), (*R*) or (*S*)-2,3-dihydroxypropylsulfinyl, (*RS*), (*R*) or (*S*)-

2,2-dimethyl-1,3-dioxolan-4-ylmethyl sulfonyl, or (*RS*), (*R*) or (*S*)-2,3-dihydroxypropylsulfonyl.

Yet another more preferred group of compounds is that wherein R⁶ is heterosubstituted cyclohexylamino.

Within these preferred and more preferred groups of compounds, an even more preferred group of compounds is that wherein R³ is alkyl, preferably ethyl or methyl, more preferably methyl.

Within these preferred, more preferred, and even more preferred groups of compounds, a particularly preferred group of compounds is that wherein:

R¹ and R² are hydrogen; or R¹ is halogen, preferably chloro and R² is hydrogen; and
R⁴ and R⁵ are hydrogen, alkyl, halogen, alkoxy, cyano or nitro, preferably hydrogen, chloro or fluoro, more preferably R⁴ and R⁵ are both hydrogen or one of R⁴ and R⁵ is fluoro and the other is hydrogen, or both of R⁴ and R⁵ are fluoro.

Compounds of this invention can be made by the methods depicted in the reaction schemes shown below.

The starting materials and reagents used in preparing these compounds are either available from commercial suppliers such as Aldrich Chemical Co., (Milwaukee, Wisconsin, USA), Bachem (Torrance, California, USA), Emka-Chemie, or Sigma (St. Louis, Missouri, USA) or are prepared by methods known to those skilled in the art following procedures set forth in references such as Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-15 (John Wiley and Sons, 1991); Rodd's Chemistry of Carbon Compounds, Volumes 1-5 and Supplementals (Elsevier Science Publishers, 1989), Organic Reactions, Volumes 1-40 (John Wiley and Sons, 1991), March's Advanced Organic Chemistry, (John Wiley and Sons, 4th Edition), and Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989). These schemes are merely illustrative of some methods by which the compounds of this invention can be


synthesized, and various modifications to these schemes can be made and will be suggested to one skilled in the art having referred to this disclosure.

The starting materials and the intermediates of the reaction may be isolated and purified if desired using conventional techniques, including but not limited to filtration, distillation, crystallization, chromatography, and the like. Such materials may be characterized using conventional means, including physical constants and spectral data.

Schemes 1-4 describe alternative methods to prepare the compounds of Formula (I).

Compounds of Formula (I) where R^3 is methyl, R^6 is $-NHR^{10}$, and other groups are as defined in the Summary of the Invention can be prepared as shown in Scheme 1 below.

Scheme 1



5 Acylation of N-methylindole of formula 1 with oxalyl chloride in an ethereal solvent such as diethyl ether provides a indole-3-glyoxylyl chloride of formula 2. The reaction is typically carried out between 0° C and room temperature, preferably at 0° C. Compounds of formula 1 are commercially available or they can be prepared by methods well known in the art. For example, 1-methylindole, 4-methoxy-1-methylindole, and 5-bromo-1-methylindole are commercially available. 5-chloro-1-methylindole can be prepared by alkylation of commercially available 5-chloroindole by methods well known in the art such as treating 5-chloroindole with alkylhalide in the presence of a base such as sodium
10 hydride in solvents such as dimethylformamide. Similarly, various other substituted indoles such as 5-fluoroindole and 4-, 5-, 6-, or 7-dimethylindole that are also commercially available and can be converted to the N-alkylindoles by alkylation as described above.

15 Condensation of 2 with a nitrophenylacetic acid of formula 3 provides 3-indolino-4-(nitrophenyl)-2,5-furandione of formula 4. The reaction is carried out in an inert organic solvent such as methylene chloride, chloroform, and the like and in the presence of a non-nucleophilic organic base such as triethylamine, diisopropylamine, and the like. Nitrophenylacetic acids of formula 3 are
20 commercially available. For example 2-, 3-, and 4-nitrophenylacetic acids are commercially available from Aldrich. Other nitrophenyl acetic acids may be prepared from the corresponding cyano-halobenzenes by homologation of the cyano group to an acetic acid side chain by methods well known in the art. For example, 2,6-difluoro-3-nitrocyanobenzene can be converted to 2,6-difluoro-3-nitrophenylacetic acid as follows. Hydrolysis of the cyano group in 2,6-difluoro-3-nitrocyanobenzene under acidic hydrolysis reaction conditions provides 2,6-difluoro-3-nitrobenzoic acid which is then treated with a chlorinating agent such as
25 oxalyl chloride to provide 2,6-difluoro-3-nitrobenzoyl chloride. Treatment of 2,6-difluoro-3-nitrobenzoyl chloride with diazomethane provides the corresponding diazoketone derivative which upon treatment with silver salt of benzoic acid (see *Fieser* Vol. I, pg. 1004) in the presence of triethylamine in methanol provides
30 methyl 2,6-difluoro-3-nitrophenylacetate. Hydrolysis of methyl 2,6-difluoro-3-

nitrophenylacetate under basic hydrolysis reaction conditions (e.g., lithium hydroxide in aqueous methanol) provides the desired 2,6-difluoro-3-nitrophenylacetic acid.

5 Treatment of 4 with aqueous ammonium hydroxide in a high boiling organic solvent such as N,N-dimethylformamide provides 3-indolino-4-(nitrophenyl)-1H-pyrrole-2,5-dione of formula 5. The reaction is typically carried out between 130- 140° C.


10 Reduction of the nitro group in 5 with a suitable reducing agent such as titanium trichloride in acetone provides a compound of formula 6 which is then converted to a compound of Formula (I) wherein R⁶ is a group of formula -NHR¹⁰ wherein R¹⁰ is as defined in the Summary of the Invention by methods well known in the art. For example, a compound of Formula (I) where R¹⁰ is a heteroaralkyl,
15 heterocyclic, or heterocyclalkyl group such as 2-imidazolylmethyl, 2,2-dimethyl-1,3-dioxan-5-yl, or 2,2-dimethyldioxolan-4-ylmethyl can be prepared by reacting a compound of formula 6 with 2-imidazole-carboxyaldehyde, 2,2-dimethyl-1,3-dioxan-5-one, and 2,2-dimethyldioxolan-4-carboxyaldehyde respectively, under reductive amination reaction conditions i.e., carrying out the reaction in the
20 presence of a suitable reducing agent (e.g., sodium cyanoborohydride, sodium triacetoxylborohydride, and the like) and an organic acid (e.g., glacial acetic acid, trifluoroacetic acid, and the like) at ambient temperature. Suitable solvents for the reaction are halogenated hydrocarbons (e.g., 1,2-dichloroethane, chloroform, and the like). 2,2-Aldehydes and ketones such as 2-imidazolecarboxyaldehyde, 2,2-dimethyl-1,3-dioxan-5-one, and 2,2-dimethyldioxolan-4-carboxyaldehyde are
25 commercially available. 2,2-Dimethyldioxolane-4-carboxyaldehyde can be prepared by the procedure described in Dumont, von R., et al., *Helv. Chim. Acta*, 66, 814, (1983).

30 As will be apparent to a person skilled in the art, a compound of Formula (I) can be converted to other compounds of Formula (I). For example, acidic

hydrolysis of compound (I) wherein R^{10} is 2,2-dimethyldioxolan-4-ylmethyl provides a compound of Formula (I) wherein R^{10} is a 2,3-dihydroxy-propyl group.

Compounds of Formula (I) where R^3 is methyl, R^6 is heteroalkyl, heterocyclyl or $-OR^8$ wherein R^8 is heteroalkyl, heteroaralkyl, heterocyclyl, or heterocyclylalkyl, and other groups are as defined in the Summary of the Invention can be prepared as shown in Scheme 2 below.

Scheme 2



Reaction of a compound of formula 2 with a compound of formula 7 (where R^6 is heteroalkyl, heterocyclyl, or $-OR^8$ wherein R^8 is heteroalkyl, heteroaralkyl, heterocyclyl, or heterocyclylalkyl) under the reaction conditions described in Scheme 1 above provides a 3-indolino-4-phenyl-2,5-furandione of formula 8.

Compounds of formula 7 where R^6 is heteroalkyl, heterocyclyl, or $-OR^8$ (wherein R^8 is heteroalkyl, heteroaralkyl, heterocyclyl, or heterocyclylalkyl) can be prepared by methods well known in the art. For example, 3-heterocyclyl-phenylacetic acid can be prepared under catalytic amination reaction conditions by reacting methyl 3-bromophenylacetate with a suitable heterocycle (such as morpholine, piperidine, pyrrolidine, and the like) in the presence of a substituted

phosphorous ligand such as 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (BINAP) and a palladium catalyst such as tris(dibenzylideneacetone)dipalladium ($\text{Pd}_2(\text{dba})_3$), followed by de-esterification of the resulting methyl 3-heterocyclylphenylacetate under basic hydrolysis reaction conditions.


5 3-(2-Aminoethyl)phenylacetic acid can be prepared by coupling methyl 3-bromophenylacetate with nitroethylene under Heck reaction conditions to give methyl 3-(2-nitrovinyl)phenyl acetate, followed by reduction of the alkene bond and the nitro group by methods well known in the art, e.g. catalytic hydrogenation
10 followed by hydride reduction. Hydrolysis of methyl 3-(2-aminoethyl)-phenylacetate under basic conditions then provides 3-(2-aminoethyl)phenylacetic acid. It will be recognized by a person skilled in the art that the amino group in 3-(2-aminoethyl)phenylacetic acid would be protected with a suitable protecting group prior to reacting it with compound 2.

15 Compounds of formula 7 where R^6 is $-\text{OR}^8$ (wherein R^8 is heteroaralkyl or heterocyclylalkyl) can be prepared by reacting hydroxyphenylacetic acid with an alkylating agent of formula R^8X wherein R^8 is as defined above and X is a leaving group under alkylation reaction conditions such as halogen (Cl, Br, I), tosylate, mesylate, triflate, and the like. The reaction is typically carried out in the presence
20 of a base such as cesium carbonate, potassium carbonate and the like, and in an aprotic polar organic solvent such as acetonitrile, N-methylpyrrolidine, and the like. Alkylating agents such as 2-chloromethylpyridine, 2,2-dimethyl-1,3-dioxolan-4-ylmethyl *p*-toluenesulfonate, 1-(3-chloropropyl)piperidine, and 4-(2-chloroethyl)morpholine, and the like are commercially available.

25 Compound 8 which is then converted to a compound of Formula (I) as described in Scheme I above. Again, as discussed above, a compound of Formula (I) can be converted to other compounds of Formula (I). For example, acidic hydrolysis of compound (I) wherein R^8 is 2,2-dimethyldioxolan-4-ylmethyl
30 provides a compound of Formula (I) wherein R^8 is a 2,3-dihydroxy-propyl group (i.e., R^8 is heteroalkyl group).

Alternatively, compounds of Formula (I) where R³ is methyl and other groups are as defined in the Summary of the Invention can be prepared as shown in Scheme 3 below.

Scheme 3




Reaction of a compound of formula **7** with a chlorinating agent such as oxalyl chloride in the presence of a catalytic amount of dimethylformamide and in an inert solvent such as dichloromethane, chloroform, and the like, provides the acid chloride. Treatment of the acid chloride with aqueous ammonia at 0 °C provides phenylacetamide of formula **9**. Coupling of **9** with methyl indoleglyoxalate **10** provides a compound of Formula (I). The coupling reaction is carried out in the presence of a strong organic base such as *tert*-butoxide and in an ethereal organic solvent such as tetrahydrofuran and the like. Compounds of formula **10** where R^1 and R^2 vary can be prepared from 1-methylindole by the procedures described in Faul, M., et. al., *J. Org. Chem.*, 63, 6053-6058, (1998).

A compound of Formula (I) can be converted to other compounds of Formula (I) as described above. This synthetic route is particularly suitable for preparing compounds of Formula (I) wherein R^6 is heterocyclyl.

Alternatively, compounds of Formula (I) where R^3 is methyl and other groups are as defined in the Summary of the Invention can be prepared as shown in Scheme 4 below.

Scheme 4



5

10


Treatment of an iodobenzene of formula 11 with bis(pinacolato)diborane in the presence of a palladium catalyst such as $\text{PdCl}_2(\text{dppf})$, followed by coupling of the resulting borate with a 4-bromo-3-(1-methylindol-3-ylmethyl)-1-methylpyrrole-2,5-dione 12 under Suzuki reaction conditions provides a 4-phenyl-3-(1-methylindol-3-ylmethyl)-1-methylpyrrole-2,5-dione 13. Compounds of formula 12 can be prepared by methods well known in the art. For example, 4-bromo-3-(1-methylindol-3-yl)-1-methylpyrrole-2,5-dione can be prepared by method described in Brenner, M. et al., *Tet. Lett.*, 44, 2887, (1988).

Treatment of 13 with a strong base such as sodium hydroxide, potassium hydroxide, and the like in an aqueous alcoholic solvent such as ethanol provides a 4-phenyl-3-(1-methylindol-3-ylmethyl)-1-H-pyrrole-2,5-dione 8 which is then converted to a compound of Formula (I) as described above:

5

Alternatively, compounds of Formula (I) where R^3 is methyl and other groups are as defined in the Summary of the Invention can be prepared as shown in Scheme 5 below.

Scheme 5



10

The acylation of N-methylindole of formula 1 with oxalyl chloride as described above, followed by quenching with aqueous ammonium at 0 °C provides a compound of formula 14. Coupling of 14 with a methyl phenylacetate of formula 15 provides a compound of Formula (I). The coupling reaction is carried out in the presence of a strong organic base such as *tert*-butoxide and in an ethereal organic solvent such as tetrahydrofuran and the like.

15

20

The 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives of Formula (I) inhibit GSK-3 β . The compounds and compositions containing them are therefore useful in the treatment of diseases mediated by GSK-3 β diseases such as Alzheimer's disease, obesity, diabetes, atherosclerotic cardiovascular disease,

polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency and cancer.

In addition, Applicants have discovered that inhibition of GSK-3 β activity
5 reduces the level of CD4+ T-helper 2 cells (Th2) which produce cytokines such as
IL-4, IL-5, IL-13, and promote IgE production and eosinophil differentiation. CD4
T-cells can differentiate into functionally distinct subsets with different profiles of
cytokine production. Type 1 T Helper cells (Th1) produce IFN-g and IL-2 and
promote cell mediated immunity. Type 2 T Helper cells (Th2) produce IL-4 and
10 IL-5 and promote IgE production and eosinophil differentiation. An imbalance in
the type of T-cell response appears to underlie the susceptibility to asthma and
allergic diseases. Through genetic studies Applicants have discovered that GSK-
3 β controls the activity of TCF7 (also known as TCF1 in the literature) thereby
controlling whether or not naïve T-cells differentiate into Th1 or Th2 cells.
15 Furthermore, Applicants have discovered that inhibitors of GSK-3 β inhibit Th2 cell
development. This is an important discovery because it has been established that
Th2 specific cytokines play a key role in the pathogenesis of diseases such as
allergies and asthma. Specifically, IL-13 is implicated in airway hyper-
responsiveness and mucus hypersecretion, as shown in murine studies of IL-13
20 delivery to the lungs of mice (Wills-Karp, M. et al., *Science* 282, 2258-2261
(1998); Grunig, G. et al., *Science* 282, 2261-2263 (1998)). Also, increased
expression of IL-13 has been observed in airways of asthma patients which
supports a role for IL-13 in the disease (Kroegel, C., et al., *European Respiratory
Journal*, 9, 899-904, (1996). Furthermore, the total serum IgE levels and tissue
25 eosinophilia, characteristic conditions of allergy and asthma, correlate with disease
severity in atopic asthma patients (Yssel, H. et al., *Clinical and Experimental
Allergy*, 28, Suppl 5: 104-109 (1998)). Prior to Applicants' discovery that GSK-3 β
controls TCF7 and thereby modulates Th2 cell differentiation, it was not known that
inhibition of GSK-3 β would provide a general method of treating diseases such as
30 asthma (particularly atopic asthma), allergies, allergic rhinitis, all of which are
caused by an excess of Th2 cells and their associated cytokines. As shown in the
Examples below, Applicants have confirmed the ability of GSK-3 β inhibitors to

treat the asthmatic response in a variety of art-accepted *in vivo* models. Therefore, Applicants' invention encompasses the use of inhibitors of GSK-3 β to treat wide range of allergies, asthma, and other diseases characterized by excess Th2 cytokines.

5

A murine genetic approach was used to identify a genetic locus that differentially regulated CD4 T cell subset differentiation and responsiveness to IL-12. The genetic background of the murine strain influences CD4 T cell development. The development of Th2 cells is favored in one strain (Balb/C) of mice, while T cells from another strain (B10.D2) have a greater capacity to maintain IL-12 responsiveness and Th1 development *in vivo* and *in vitro*. Analysis of experimental intercrosses between Balb/C and B10.D2 mice expressing transgenic T cell antigen receptors led to identification of a locus located within a 0.5 cM region of murine chromosome 11 which controls maintenance of IL-12 responsiveness (Guler M. L. et al., J. Immunol. 162, 1339-1347, 1999). This region was syntenic to the locus on human chromosome 5q31, which has been associated with elevated serum IgE levels and susceptibility to asthma (Review: Cookson, W., Nature 402, Suppl. B5-B11, 1999). Positional cloning of this genetic locus was performed by analysis of the chromosomal sequence within this chromosomal region, and by analysis of gene expression.

10

15

20

25

30

We have demonstrated that TCF7 regulates T helper cell differentiation. TCF7, which is expressed only in T cells, was shown to be expressed in resting murine Th1, but not Th2 cells. This factor was also induced by IFN-gamma (Figure 2B); and recognition elements for TCF-7 were found in the promoter regions of genes expressed in Th1 cells; IFN-gamma, IFN-alpha, IL-18 and the beta-2 subunit of the IL12 receptor. We have also shown that inhibition of GSK-3 β will increase the level of β -catenin in T cells. β -catenin does then accumulate in the nucleus and act as cofactor for TCF7 to activate gene transcription (Example II, Figure 1). Therefore, GSK-3 β inhibitors will inhibit Th2 cell development. We have confirmed this by demonstrating that Th2 cytokine levels are reduced in cells treated with GSK-3 β inhibitors (Examples III and IV).

Preferably, the GSK-3 β inhibitors used for treatment of diseases characterized by excess Th2 cytokines will be selective for GSK-3 β relative to other kinases, particularly PKC, p38 kinase, lck and cdk2, by a ratio of at least 10:1, more preferably 100:1 (based on their respective IC₅₀'s). Determination of the relative IC₅₀'s of a putative inhibitor may be accomplished by standard kinase activity assays well known to one of skill in the art. Such selective modulation permits the selective treatment of diseases characterized by excess Th2 cell production without affecting biological processes mediated by other kinases

Furthermore, since GSK-3 α and GSK-3 β isoforms have 95% identical catalytic domains, it is contemplated that the compounds of the present invention would be useful in treating diseases mediated by GSK-3 α .

The ability of the compounds of Formula (I) to inhibit GSK-3 β was measured by *in vitro* assays such as ligand binding assay and inhibition of β -catenin degradation assay as described in detail in Biological Example I and II below. The ability of the compounds of this invention to inhibit secretion of IL-4 and IL-13 from human T-cells was measured by *in vitro* assay described in detail in Biological Example III below. The ability of the compounds of this invention to inhibit secretion of IL-4, IL-5 and IL-13 from murine T-cells was measured by *in vitro* assay described in detail in Biological Example IV below. The ability of the compounds of this invention to inhibit leukocyte infiltration into the lungs was measured by *in vivo* assay described in detail in Biological Example V below. The ability of the compounds of this invention to reduce the IgE levels was measured by *in vivo* assay described in detail in Biological Example VI below.

In general, the compounds of this invention will be administered in a therapeutically effective amount by any of the accepted modes of administration for agents that serve similar utilities. The actual amount of the compound of this invention, i.e., the active ingredient, will depend upon numerous factors such as the severity of the disease to be treated, the age and relative health of the subject, the potency of the compound used, the route and form of administration, and other

factors. The drug can be administered more than once a day, preferably once or twice a day.

Therapeutically effective amounts of compounds of Formula (I) may range
5 from approximately 1 mg to 5 mg per kilogram body weight of the recipient per day; preferably about 3 mg/kg/day. Thus, for administration to a 70 kg person, the dosage range would be about 70 to 350 mg/day, most preferably be about 200 mg per day.

10 In general, compounds of this invention will be administered as pharmaceutical compositions by any one of the following routes: oral, systemic (e.g., transdermal, intranasal or by suppository), or parenteral (e.g., intramuscular, intravenous or subcutaneous) administration. The preferred manner of administration is oral using a convenient daily dosage regimen which can be
15 adjusted according to the degree of affliction. Compositions can take the form of tablets, pills, capsules, semisolids, powders, sustained release formulations, solutions, suspensions, elixirs, aerosols, or any other appropriate compositions. Another preferred manner for administering compounds of this invention is inhalation. This is an effective method for delivering a therapeutic agent directly to
20 the respiratory tract for the treatment of diseases such as asthma and similar or related respiratory tract disorders (see U. S. Patent 5,607,915).

The choice of formulation depends on various factors such as the mode of drug administration and bioavailability of the drug substance. For delivery via
25 inhalation the compound can be formulated as liquid solution, suspensions, aerosol propellants or dry powder and loaded into a suitable dispenser for administration. There are several types of pharmaceutical inhalation devices-nebulizer inhalers, metered dose inhalers (MDI) and dry powder inhalers (DPI). Nebulizer devices produce a stream of high velocity air that causes the therapeutic agents (which are
30 formulated in a liquid form) to spray as a mist which is carried into the patient's respiratory tract. MDI's typically are formulation packaged with a compressed gas. Upon actuation, the device discharges a measured amount of therapeutic agent by

compressed gas, thus affording a reliable method of administering a set amount of agent. DPI dispenses therapeutic agents in the form of a free flowing powder that can be dispersed in the patient's inspiratory air-stream during breathing by the device. In order to achieve a free flowing powder, the therapeutic agent is formulated with an excipient such as lactose. A measured amount of the therapeutic agent is stored in a capsule form and is dispensed with each actuation.

Recently, pharmaceutical formulations have been developed especially for drugs that show poor bioavailability based upon the principle that bioavailability can be increased by increasing the surface area i.e., decreasing particle size. For example, U.S. Pat. No. 4,107,288 describes a pharmaceutical formulation having particles in the size range from 10 to 1,000 nm in which the active material is supported on a crosslinked matrix of macromolecules. U.S. Pat. No. 5,145,684 describes the production of a pharmaceutical formulation in which the drug substance is pulverized to nanoparticles (average particle size of 400 nm) in the presence of a surface modifier and then dispersed in a liquid medium to give a pharmaceutical formulation that exhibits remarkably high bioavailability.

The compositions are comprised of in general, a compound of Formula (I) in combination with at least one pharmaceutically acceptable excipient. Acceptable excipients are non-toxic, aid administration, and do not adversely affect the therapeutic benefit of the compound of Formula (I). Such excipient may be any solid, liquid, semi-solid or, in the case of an aerosol composition, gaseous excipient that is generally available to one of skill in the art.

25

Solid pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk and the like. Liquid and semisolid excipients may be selected from glycerol, propylene glycol, water, ethanol and various oils, including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil,

30

etc. Preferred liquid carriers, particularly for injectable solutions, include water, saline, aqueous dextrose, and glycols.


Compressed gases may be used to disperse a compound of this invention in aerosol form. Inert gases suitable for this purpose are nitrogen, carbon dioxide, etc. Other suitable pharmaceutical excipients and their formulations are described in Remington's Pharmaceutical Sciences, edited by E. W. Martin (Mack Publishing Company, 18th ed., 1990).

The amount of the compound in a formulation can vary within the full range employed by those skilled in the art. Typically, the formulation will contain, on a weight percent (wt%) basis, from about 0.01-99.99 wt% of a compound of Formula (I) based on the total formulation, with the balance being one or more suitable pharmaceutical excipients. Preferably, the compound is present at a level of about 1-80 wt%. Representative pharmaceutical formulations containing a compound of Formula (I) are described below.

EXAMPLES

Abbreviations used in the examples are defined as follows: "HCl" for hydrochloric acid, "DMF" for dimethylformamide, "NaOH" for sodium hydroxide, "KOH" for potassium hydroxide, "DMSO" for dimethylsulfoxide, "NaHCO₃" for sodium bicarbonate, "NaCl" for sodium chloride, "K₂CO₃" for potassium carbonate, "Na₂CO₃" for sodium carbonate, "LiOH" for lithium hydroxide, "Et₃N" for triethylamine, "NH₃ (aq)" for ammonium hydroxide, "CH₂Cl₂" for methylene chloride, "MeOH" for methanol, "EtOH" for ethanol, "Ph₃P" for triphenylphosphine, "CsCO₃" for cesium carbonate, "BINAP" for 2,2-bis-(diphenylphosphino)-1,1'-binaphthyl, "Pd₂(dba)₃" for tris(dibenzylideneacetone)-dipalladium, "NaCNBH₃" for sodium cyanoborohydride, "THF" for tetrahydrofuran, "Na₂SO₄" for sodium sulfate, "RT" for room temperature, "PTLC" for preparatory thin layer chromatography, "SiO₂" for silica gel, "EtOAc" for ethyl acetate, "APMA" for aminophenyl-mercuric acetate, "IL-1" for interleukin-1, and "RPMI" for Roswell Park Memorial Institute.

Example 1

Synthesis of 3-(1-methylindol-3-yl)-4-[3-((*R*)-2,2-dimethyl-1,3-dioxolan-4-ylmethoxy)phenyl]-1H-pyrrole-2,5-dioneStep 1

Thionyl chloride (17 ml; 0.64 mol) was added dropwise to methanol at 0 °C. After the completion of the addition, the reaction mixture was stirred at 0 °C for 10 min., and then 3-hydroxyphenylacetic acid (25 g, 0.16 mol) was added. The resulting reaction mixture was stirred at room temperature for 2 hours. Volatiles were removed and the residue was partitioned between water and ethyl acetate. The organic layer was separated, washed with H₂O, NaHCO₃, and NaCl (sat.) and dried over Na₂SO₄. The crude product was purified on a silica gel column with 20% EtOAc in hexane to give methyl 3-hydroxyphenylacetate as a colorless oil (25 g, 94% yield).

Step 2

Methyl 3-hydroxyphenylacetate (20 g, 0.12 mol), (*R*)-2,2-dimethyl-1,3-dioxolan-4-ylmethyl *p*-tosylate (51.7 g, 1.5 eq.) and K₂CO₃ (50 g, 3eq.) in *N*-methylpyrrolidinone was heated at 96 °C overnight. The reaction mixture was cooled to room temperature, quenched with H₂O, and partitioned between H₂O and EtOAc. The organic layer was separated, washed with H₂O and NaCl (sat.), and then dried over Na₂SO₄. The crude product was purified on a silica gel column with 20% EtOAc in hexane to give methyl 3-((*R*)-2,2-dimethyl-1,3-dioxolan-4-ylmethoxy)phenylacetate as an oil (23 g, 68% yield).

Step 3

To a solution of methyl 3-((*R*)-2,2-dimethyl-1,3-dioxolan-4-ylmethoxy)phenyl-acetate (23 g, 0.08 mol) in methanol (80 ml) and water (5 ml) was added LiOH-H₂O (13.8 g, 4 eq.). After stirring the reaction mixture at room temperature for 4 h, the volatiles were removed under *vacuo* and the residue was partitioned between EtOAc and H₂O. The aqueous layer was separated, cooled with an ice bath, and then acidified with 10% aq. HCl. The acidic aqueous layer was extracted with EtOAc. The EtOAc layer was washed with NaCl (sat.), dried over Na₂SO₄, and concentrated to give 3-((*R*)-2,2-dimethyl-1,3-dioxolan-4-ylmethoxy)phenylacetic acid as a white solid (22 g, >99% yield).

Step 4

Oxalyl chloride (1.05 eq., 4.15 ml) was added dropwise to a solution of N-methylindole (5.8 ml, 50 mmol) in diethyl ether (395 ml) at 0 °C. Yellow precipitates were formed. After the completion of the addition, the reaction mixture was stirred at 0 °C for 30 min., and then the volatiles were removed under *vacuo*. The residue was re-dissolved in dichloromethane (375 ml) and added to a solution of 3-((*R*)-2,2-dimethyl-1,3-dioxolan-4-ylmethoxy)phenylacetic acid (13.3 g, 50 mmol) and Et₃N (12.5 ml, 2.2eq.) in dichloromethane (375 ml) at 0 °C. The resulting mixture was stirred at 0 °C and then allowed to warm up slowly to room temperature. After stirring overnight, the volatiles were removed and the residue was purified on a silica gel column with dichloromethane to give 3-(1-methylindol-3-yl)-4-{3-((*R*)-2,2-dimethyl-1,3-dioxolan-4-ylmethoxy)-phenyl}furan-2,5-dione (5.4 g, 27% yield).

Step 5

3-(1-Methylindol-3-yl)-4-[3-((*R*)-2,2-dimethyl-1,3-dioxolan-4-ylmethoxy)-phenyl]furan-2,5-dione (5.4 g, 13.7 mmol) was dissolved in DMF (50 ml) and was diluted with NH₃ (aq.) (100 ml). The reaction mixture was then heated at 140 °C for 5 hours, cooled to room temperature and then diluted with water. The product was extracted with EtOAc and the organic layer was washed with NaCl (sat.) and dried over sodium sulfate to give the crude product which was

further purified by re-crystallization from dichloromethane and hexane to give 3-(1-methylindol-3-yl)-4-[3-((*R*)-2,2-dimethyl-1,3-dioxolan-4-ylmethoxy)phenyl]-1H-pyrrole-2,5-dione (5 g).

5 ¹H NMR (DMSO-d₆): δ 11.08 (s, NH), 8.04 (s, 1H), 7.49 (d, 1H, J=8.2), 7.22 (t, 1H, J=8.0), 7.12 (t, 1H, J=7.0), 6.97 (m, 3H), 6.76 (t, 1H, J=7.5), 6.33 (d, 1H, J=8.0), 4.23 (m, 1H), 3.96 (dd, 1H, J=6.5, 8.4), 3.91 (s, 3H), 3.77 (d, 1H, J=5.1), 3.60 (dd, 1H, J=6.1, 8.2), 1.30 (s, 3H), 1.27 (s, 3H); MS (EI): M⁺ 432.

10 Following the procedure described above, but substituting 3-hydroxyphenylacetic acid with 2-hydroxyphenylacetic acid gave 3-(1-methylindol-3-yl)-4-[2-((*RS*)-2,2-dimethyl-1,3-dioxolan-4-ylmethoxy)phenyl]-1H-pyrrole-2,5-dione. ¹H NMR (DMSO-d₆): δ 10.99 (s, NH), 8.03 (s, 1H), 7.46 (d, 1H, J=7.2), 7.38 (t, 1H, J=5.4), 7.27 (d, 1H, J=7.5), 7.11 (t, 1H, J=7.1), 7.03 (m, 2H), 15 6.64 (t, 1H, J=7.1), 6.32 (d, 1H, J=7.1), 4.3 (br.s. 2H), 3.88 (s, 3H), 3.68 (br.s. 2H), 3.2 (br.s. 1H), 1.19 (s, 6H); M. pt. 220.8-221.2 °C; MS (EI): M⁺ 432;


Following the procedure described above, but substituting 3-hydroxyphenylacetic acid with 4-hydroxyphenylacetic acid gave 3-(1-methylindol-20 3-yl)-4-[4-((*R*)-2,2-dimethyl-1,3-dioxolan-4-ylmethoxy)phenyl]-1H-pyrrole-2,5-dione. ¹H NMR (DMSO-d₆): δ 11.00 (s, NH), 7.97 (s, 1H), 7.48 (d, 1H, J=6.3), 7.36 (d, 2H, J=8.9), 7.13 (t, 1H, J=7.2), 6.90 (d, 2H, J=8.9), 6.78 (t, 1H, J=7.2), 6.42 (d, 1H, J=8.0), 4.39 (m, 1H), 4.06 (m, 3H), 3.90 (s, 3H), 3.73 (m, 1H), 1.35 (s, 3H), 1.30 (s, 3H); MS (EI): M⁺ 432.

25 Following the procedure described above, but substituting (*R*)-2,2-dimethyl-1,3-dioxolan-4-ylmethyl *p*-tosylate with (*S*)-2,2-dimethyl-1,3-dioxolan-4-ylmethyl *p*-tosylate gave 3-(1-methylindol-3-yl)-4-[3-((*S*)-2,2-dimethyl-1,3-dioxolan-4-ylmethoxy)phenyl]-1H-pyrrole-2,5-dione.

30

Example 2

Synthesis of 3-(1-methylindol-3-yl)-4-{3-[(*R*)-2,3-dihydroxypropyloxy]phenyl}-1H-pyrrole-2,5-dione



Step 1

Toluenesulfonic acid (100 mg) was added to a solution of 3-(1-methylindol-3-yl)-4-[3-((*R*)-2,2-dimethyl-1,3-dioxolan-4-ylmethyloxy)phenyl]-1H-pyrrole-2,5-dione (4.3 g) in methanol (100 ml) and water (10 ml) and the reaction mixture was heated at 50 °C overnight. The volatiles were removed and the residue was partitioned between water and EtOAc. The organic layer was washed with NaCl (sat.) and dried over sodium sulfate. The crude product was purified on a silica gel column with 5% MeOH in CH₂Cl₂ and further purified by recrystallization from CH₂Cl₂/hexane to give 3-(1-methylindol-3-yl)-4-{3-[(*R*)-2,3-dihydroxypropyloxy]phenyl}-1H-pyrrole-2,5-dione (2.46 g). ¹H NMR (DMSO-d₆): δ 11.05 (s, NH), 8.03 (s, 1H), 7.48 (d, 1H, J=8.2), 7.15 (m, 1H), 7.02 (s, 1H), 6.92 (m, 1H), 6.92 (m, 1H), 6.76 (t, 1H, J=7.3), 6.37 (t, 1H, J=8.0), 4.89 (d, OH, J=4.7), 4.61 (t, OH, J=5.8), 3.90 (s, 3H), 3.85 (m, 1H), 3.72 (m, 2H), 3.37 (m, 2H); MS (EI): M⁺ 392; M.pt. 177.7-178.0 °C; Anal (C₂₂H₂₀N₂O₅·0.15H₂O): C, H, N.

Following the procedure described above but substituting 3-(1-methylindol-3-yl)-4-[3-((*R*)-2,2-dimethyl-1,3-dioxolan-4-ylmethyloxy)phenyl]-1H-pyrrole-2,5-dione with 3-(1-methylindol-3-yl)-4-[2-((*R*)-2,2-dimethyl-1,3-dioxolan-4-ylmethyloxy)phenyl]-1H-pyrrole-2,5-dione gave 3-(1-methylindol-3-yl)-4-{2-[(2,3-dihydroxypropyloxy)-phenyl]-1H-pyrrole-2,5-dione. ¹H NMR (DMSO-d₆): δ 10.96 (s, NH), 7.98 (s, 1H), 7.47 (d, 1H, J=8.1), 7.36 (t, 1H, J=8.8), 7.23 (d, 1H, J=7.2), 7.11 (t, 1H, J=7.1), 6.95 (m, 2H), 6.66 (t, 1H, J=7.3), 6.33 (d, 1H, J=8.0),


3.87 (s, 3H), 3.6 (br.s. 1H), 3.2 (br.s. 2H), 3.1 (br.s. 2H); M. pt. 245.0-247.1 °C;
MS (EI): M^+ 392; Anal ($C_{22}H_{20}O_5N_2 \cdot 1.20H_2O$): C, N, H.

Following the procedure described above but substituting 3-(1-methylindol-
3-yl)-4-[3-((*R*)-2,2-dimethyl-1,3-dioxolan-4-ylmethoxy)phenyl]-1H-pyrrole-2,5-
dione with 3-(1-methylindol-3-yl)-4-[4-((*R*)-2,2-dimethyl-1,3-dioxolan-4-
ylmethoxy)phenyl]-1H-pyrrole-2,5-dione gave 3-(1-methylindol-3-yl)-4-{4-
[[(*R*)-2,3-dihydroxypropyloxy]-phenyl]-1H-pyrrole-2,5-dione. 1H NMR (DMSO-
 d_6): δ 11.00 (s, NH), 7.97 (s, 1H), 7.48 (t, 1H, $J=8.2$), 7.34 (d, 2H, $J=8.9$), 7.13 (t,
1H, $J=7.2$), 6.87 (d, 2H, $J=8.9$), 6.86 (t, 1H, $J=7.2$), 6.43 (d, 1H, $J=8.1$), 4.00 (m,
1H), 3.90 (s, 3H), 3.8 (m, 2H), 3.43 (m, 2H); M. pt. 220.3-222.7 °C; MS (EI): M^+
392.

Following the procedure described above, but substituting 3-(1-
methylindol-3-yl)-4-[3-((*R*)-2,2-dimethyl-1,3-dioxolan-4-ylmethoxy)phenyl]-1H-
pyrrole-2,5-dione with 3-(1-methylindol-3-yl)-4-{3-((*S*)-2,2-dimethyl-1,3-
dioxolan-4-ylmethoxy)phenyl]-1H-pyrrole-2,5-dione gave 3-(1-methylindol-3-
yl)-4-{3-[(*S*)-2,3-dihydroxypropyloxy]-phenyl]-1H-pyrrole-2,5-dione. MS (EI):
 M^+ 392; M. pt. 176.9-178.1 °C.

Example 3

Synthesis of 3-(1-methylindol-3-yl)-4-[3-(2-morpholin-4-ylethoxy)phenyl]-
1H-pyrrole-2,5-dione



Step 1

To a stirred solution of 3-iodophenol (2.2 g, 10 mmol), N-(2-hydroxyethyl)morpholine (2 eq. 2.4 ml) and Ph_3P (2 eq. 5.24 g) in THF (90 ml) at 0 °C was added dropwise a solution of diisopropylazodicarboxylate (2 eq. 3.96 g) in THF (20 ml). The resulting solution was stirred at room temperature overnight and was then quenched with NaHCO_3 . The product was extracted with EtOAc and the EtOAc layer was washed with NaCl (sat.), dried over sodium sulfate. The crude mixture was then purified on a silica gel column with 25% acetone in hexane to give 3-(2-morpholin-4-ylethyloxy)iodobenzene (2.8 g, 84% yield).

Step 2

A flask charged with 3-(2-morpholin-4-ylethyloxy)iodobenzene (0.33 g, 1 mmol), bis(pinacolato)diboron (0.279 g, 1.1 mmol), potassium acetate (0.294 g, 3 mmol) and $\text{PdCl}_2(\text{dppf})$ (48 mg, 0.06 mmol) was flushed with nitrogen. N,N-Dimethylformamide (6 ml) was added and the reaction mixture was stirred at 80 °C for 3 hours and then cooled to room temperature. 3-Bromo-4-(1-methylindol-3-yl)-1-methylpyrrole-2,5-dione (0.255 g, 0.8 mmol) (synthesized according to the procedures described in Brenner, M. et al., *Tet. Lett.* 44, 2887, (1988)) was added to the reaction mixture, followed by the addition of $\text{PdCl}_2(\text{dppf})$ (48 mg, 0.06 mmol) and 2 M aq. Na_2CO_3 (2.5 ml). The resulting mixture was stirred at 80 °C for 2.5 hours, then cooled to room temperature, and quenched with H_2O . The product was extracted with EtOAc. The EtOAc layer was washed with H_2O , NaCl (sat.), dried over Na_2SO_4 , and concentrated. Purification of the crude product on a silica gel column with 2/3/5 of acetone/ CH_2Cl_2 /hexane gave 3-(1-methylindol-3-yl)-4-[3-(2-morpholin-4-ylethyloxy)-phenyl]-1-methylpyrrole-2,5-dione as an orange-red oil. (0.25 g, 70% yield).

Step 3

3-(1-Methylindol-3-yl)-4-[3-(2-morpholin-4-ylethyloxy)phenyl]-1-methylpyrrole-2,5-dione (0.22 g, 0.5 mmol) was dissolved in EtOH (10 ml) and a solution of KOH (1.5 g) in H_2O (2.5 ml) was added. After the reaction mixture was refluxed for 3 h, it was cooled to room temperature, followed by evaporation

of EtOH. The residue was acidified with aq. HCl to pH=4.5. The product was extracted with EtOAc and the EtOAc layer was dried over sodium sulfate and concentrated to give 3-(1-methylindol-3-yl)-4-[3-(2-morpholin-4-ylethyloxy)phenyl]furan-2,5-dione which was in the next step without further purification.


Step 4

3-(1-Methylindol-3-yl)-4-[3-(2-morpholin-4-ylethyloxy)phenyl]furan-2,5-dione was then dissolved in DMF (5 ml) and ammonium hydroxide (10 ml) was added. The resulting mixture was heated at 140 °C for 4 hours, then cooled to room temperature, and diluted with water. The product was extracted into EtOAc. The EtOAc layer was washed with NaCl (sat.) and dried over sodium sulfate. Purification on a silica gel column with 5% (10% NH₄OH in MeOH) in CH₂Cl₂ gave 3-(1-methylindol-3-yl)-4-[3-(2-morpholin-4-ylethyloxy)phenyl]-1H-pyrrole-2,5-dione (0.21 g, >99% yield).

¹H NMR (CDCl₃): δ 7.95 (s, 1H), 7.41 (br.s. NH), 7.32 (d, 1H, J=7.2), 7.17 (m, 3H), 7.02 (s, 1H), 6.91 (d, 1H, J=6.5), 6.83 (t, 1H, J=7.1), 6.40 (d, 1H, J=8.1), 3.92 (br.s. 2H), 3.90 (s, 3H), 3.78 (br.s. 4H), 2.65 (br.s. 2H), 2.51 (br.s. 4H); MS (EI): M⁺ 431; M. pt. 197.7-199 °C; Anal (C₂₅H₂₅O₄N₃·0.3H₂O): C, H, N.

Following the procedure described above, but substituting 3-bromo-4-(1-methylindol-3-yl)-1-methylpyrrole-2,5-dione with 3-bromo-4-(1H-indol-3-yl)-1-methylpyrrole-2,5-dione, provided 3-(1H-indol-3-yl)-4-[3-(2-morpholin-4-ylethoxy)phenyl]-1H-pyrrole-2,5-dione. MS (EI): M⁺ 417.

Example 4

Synthesis of 3-(1-methylindol-3-yl)-4-(3-morpholin-4-ylphenyl)-
1H-pyrrole-2,5-dione5 Step 1

A round bottom flask flushed with argon was charged with methyl 3-bromophenyl-acetate (2.29 g, 10 mmol) (prepared from 3-bromophenylacetic acid as described in example 2, step 1), morpholine (1.05 ml, 1.2 eq.), CsCO₃ (4.55 g, 1.4 eq.), Pd₂(dba)₃ (92 mg, 0.01 eq) and BINAP (93 mg, 0.15eq.) in toluene (20 ml). The resulting mixture was heated at 100 °C overnight and then diluted with diethyl ether (120 ml). The precipitates were filtered through a Celite pad and the filtrate was concentrated and purified on a silica-gel column with 20% EtOAc in hexane to give methyl 3-(morpholin-4-yl)phenylacetate (0.55 g, 23%).

15 Step 2

To a solution of methyl 3-(morpholin-4-yl)phenylacetate (0.50 g, 2.1 mmol) in methanol (5 ml) and H₂O (1 ml) was added lithium hydroxide monohydrate (0.18 g, 2 eq.). After the reaction mixture was stirred at room temperature overnight, it was concentrated to dryness. Acetic acid was then added to the residue and the resulting mixture was partitioned between EtOAc and H₂O. The organic layer was washed with NaCl (sat.), dried over Na₂SO₄, and evaporation under *vacuo* to give 3-(morpholin-4-yl)phenylacetic acid (0.42 g).

25 Step 3

3-(Morpholin-4-yl)phenylacetic acid (0.42 g, 1.9 mmol) was dissolved in CH₂Cl₂ (5 ml) and oxalyl chloride (0.22 ml, 1.2 eq.) was added. The reaction mixture was stirred at room temperature for 2 h and then cooled to 0 °C.

Ammonium hydroxide solution (2 ml) was added dropwise. Volatiles were removed and the crude mixture was dissolved in methanol, stirred, and filtered. The filtrate was concentrated to give 3-(morpholin-4-yl)benzylamide (0.5 g) which was in the next step without any further purification).

5

Step 4

To a suspension of 3-(morpholin-4-yl)benzylamide (0.5 g) and methyl indoleglyoxalate (0.55 g, 2.5 mmol) in THF at 0 °C was added potassium *tert*-butoxide (1.0 M, 3.45 ml, 3.45 mmol) dropwise. The reaction mixture which turned orange in color was stirred at 0 °C for 1 hour and then allowed to warm to room temperature. After stirring overnight, the reaction mixture was quenched with H₂O and extracted with EtOAc. The organic layer was washed with NaCl (sat.), and dried over Na₂SO₄. Preparative TLC purification with 5% MeOH in CH₂Cl₂ gave 3-(1-methylindol-3-yl)-4-(3-morpholin-4-ylphenyl)-1H-pyrrole-2,5-dione (150 mg) as an oil which was converted to the hydrochloride salt and recrystallized from EtOAc to give 3-(1-methylindol-3-yl)-4-(3-morpholin-4-ylphenyl)-1H-pyrrole-2,5-dione hydrochloride (72 mg) as a solid.

15


¹H NMR (DMSO-d₆): δ 11.02 (s, NH), 8.02 (s, 1H), 7.48 (d, 1H, J=8.1), 7.15 (m, 2H), 6.90 (m, 2H), 6.74 (t, 1H, J=7.4), 6.34 (d, 1H, J=8.1), 3.90 (s, 3H), 3.62 (m, 4H), 2.8 (m, 4H); MS (LSIMS): (M+H)⁺ 388; M. pt. 205.3-212.6 °C.

20

Following the procedure described above, but substituting morpholine with pyrrolidine in Step 1, 3-(1-methylindol-3-yl)-4-(3-pyrrolidin-1-ylphenyl)-1H-pyrrole-2,5-dione was prepared. MS (EI): M⁺ 372.

25

Example 5

Synthesis of 3-(1-methylindol-3-yl)-4-[3-(3-aminopropoxy)phenyl]-
1H-pyrrole-2,5-dione

5

Step 1

To a solution of methyl 3-hydroxyphenyl acetate (2.49 g, 15 mmol) and 1-bromo-3-chloropropane (2.96 ml, 2eq.) in acetonitrile (50 ml) was added cesium carbonate (5.4 g, 1.1 eq.). The reaction mixture was refluxed for 24 h, then cooled to room temperature and filtered through a Celite pad. The filtrate was concentrated and the residue was purified on a silica gel column with 5/55/40 of MeOH/CH₂Cl₂/hexane to give methyl 3-(3-chloro-propyloxy)phenyl acetate (4.2 g) as an oil.

15

Step 2

To a solution of methyl 3-(3-chloropropoxy)phenyl acetate (2.87 g, 10 mmol) in methanol (15 ml) was added LiOH-H₂O (0.84 g, 2 eq.). The reaction mixture was stirred at room temperature for 2 h. Volatiles were removed and the residue was partitioned between EtOAc and water. The aqueous layer was acidified and extracted with EtOAc. The combined EtOAc layers were washed with NaCl (sat.), dried over Na₂SO₄ and concentrated to give 3-(3-chloropropoxy)phenylacetic acid (2.8 g).

20

Step 3

25

To a solution of N-methylindole (1.16 ml, 9.1 mmol) in diethyl ether (70 ml) at 0 °C was added dropwise oxalyl chloride (0.83 ml, 1.1 eq.). After the addition, the reaction mixture was stirred at 0 °C for 15 min., and the volatiles were removed under *vacuo*. The residue was re-dissolved in dichloromethane (70 ml)

and triethylamine (2.3 ml, 2eq.) was added. The reaction mixture was cooled to 0 °C and a solution of 3-(3-chloro-propyloxy)phenylacetic acid (2.73 g, 10 mmol) in dichloromethane (70 ml) was added dropwise. The resulting mixture was stirred at 0 °C, and then allowed to warm up to room temperature overnight. Volatiles were removed under *vacuo* and the residue was purified on a silica gel column with dichloromethane to give 3-(1-methylindol-3-yl)-4-[3-(3-chloropropoxy)-phenyl]furan-2,5-dione (1.1 g).

Step 4

To a solution of 3-(1-methylindol-3-yl)-4-[3-(3-chloropropoxy)phenyl]furan-2,5-dione (1.0g, 2.2 mmol) in DMF (15 ml) was added sodium azide (0.43 g, 3 eq.) and the resulting mixture was heated at 75 °C for 24 hours. The reaction mixture was cooled to room temperature and quenched with water. The product was then extracted into EtOAc. The EtOAc layer was washed with H₂O, NaCl (sat.), dried over Na₂SO₄, and concentrated *in vacuo* to give 3-(1-methylindol-3-yl)-4-[3-(3-azidopropoxy)phenyl]furan-2,5-dione (1.0 g) which was used directly in the next step without any further purification.

Step 5

To a solution of 3-(1-methylindol-3-yl)-4-[3-(3-azidopropoxy)-phenyl]furan-2,5-dione (1.0 g) in DMF (7 ml) was added ammonium hydroxide (50 ml). The reaction mixture was heated at 140 °C for 3.5 hours, then cooled to room temperature and diluted with water. The precipitates were filtered and dried to give 3-(1-methylindol-3-yl)-4-[3-(3-azidopropoxy)phenyl]-1H-pyrrole-2,5-dione (0.58 g). MS (EI): M⁺ 401.

Step 6


To a solution of 3-(1-methylindol-3-yl)-4-[3-(3-azidopropoxy)phenyl]-1H-pyrrole-2,5-dione (0.4 g, 1 mmol) in THF (20 ml) was added Ph₃P (0.25 g, 1.1 eq.), followed by the H₂O (0.017 ml). The resulting mixture was stirred at room temperature for 48 h and then concentrated *in vacuo*. The residue was purified on a silica gel column with 8% (10% NH₄OH in methanol) in CH₂Cl₂ to give 3-(1-

methylinol-3-yl)-4-[3-(3-aminopropoxy)-phenyl]-1H-pyrrole-2,5-dione (0.35 g) which was converted to HCl salt and recrystallized to give 3-(1-methylinol-3-yl)-4-[3-(3-aminopropoxy)-phenyl]-1H-pyrrole-2,5-dione (0.21 g) as the HCl salt.

5 ^1H NMR (DMSO- d_6): δ 11.1 (s, NH), 8.06 (s, 1H), 7.50 (d, 1H, $J=8.2$), 7.20 (m, 2H), 6.91 (m, 2H), 6.73 (t, 1H, $J=7.2$), 6.33 (d, 1H, $J=8.0$), 3.93 (m, 2H), 3.91 (s, 3H), 3.67 (br.s. 2H), 1.85 (m, 2H); MS (EI): M^+ 375.

Example 6

10 Synthesis of 3-(1-methylinol-3-yl)-4-[3-(2-aminoethoxy)phenyl]-1H-pyrrole-2,5-dione



15 Step 1

To a stirred solution of methyl 3-hydroxyphenylacetate (1.66 g, 10 mmol), 2-chloroethanol (1.34 ml, 2 eq.) and triphenylphosphine (5.24 g, 2 eq.) in THF (100 ml) at 0 °C was added dropwise diisopropylazodicarboxylate (3.96 ml, 2 eq.) and the resulting mixture was stirred at room temperature overnight. The reaction mixture was then quenched with NaHCO_3 and the product was extracted with EtOAc. The EtOAc layers were washed with brine, dried over sodium sulfate, and concentrated. Purification on a silica gel column with 10% EtOAc in hexane gave methyl 3-(2-chloroethoxy)phenylacetate (1.6 g, 70% yield) which was converted to 3-(1-methylinol-3-yl)-4-[3-(2-aminoethoxy)phenyl]-1H-pyrrole-2,5-dione by following the procedure described in Example 5, Steps 2-6 above.

20


25

^1H NMR (DMSO- d_6): δ 11.11 (s, NH), 8.22 (br.s. NH_2), 8.05 (s, 1H), 7.49 (d, 1H, $J=8.2$), 7.20 (m, 1H), 7.12 (s, 1H), 6.99 (dd, 1H, $J=2.6, 8.3$), 6.90 (d, 1H,

$J=7.8$), 6.75 (t, 1H, $J=7.3$), 6.35 (d, 1H, $J=8.1$), 4.09 (t, 2H, $J=5.0$), 3.91 (s, 3H), 3.15 (br.s. 2H); MS (LSIMS): $(M+H)^+$ 362; M. pt. 182.4-187 °C; Anal ($C_{21}H_{20}N_3O_3Cl \cdot 0.85H_2O$): C, H, N.

Example 7

Synthesis of 3-(1-methylindol-3-yl)-4-{3-[(2*RS*),3-dihydroxy-2-hydroxypropylamino]phenyl}-1H-pyrrole-2,5-dione



Step 1

Oxalyl chloride (4.9 ml, 56 mmol) was added dropwise to a stirred solution of 1-methylindole (6.5 ml, 51 mmol) in ether (350 ml) at 0 °C. After the completion of the addition, the reaction mixture was stirred at 0 °C for 30 min., and then the volatiles were removed under reduced pressure to afford 1-methylindole-3-glyoxylyl chloride.

Step 2

A solution of 1-methylindole-3-glyoxylyl chloride in dichloromethane (350 ml) was added to a solution of 3-nitrophenylacetic acid (8.5 g, 0.093 ml) and triethylamine (13 ml, 93 mmol) in dichloromethane (350 ml) at 0 °C. The reaction mixture was then stirred at room temperature overnight and then concentrate under reduced pressure. The crude product was purified on a silica gel column with 6:1 hexane/ethyl acetate to afford 3-(1-methylindol-3-yl)-4-(3-nitrophenyl)furan-2,5-dione (9 g, 55%).

Step 3

A solution of 3-(1-methylindol-3-yl)-4-(3-nitrophenyl)furan-2,5-dione (9 g, 26 mmol) in DMF (20 ml) was heated to about 140 °C. Aqueous ammonia (20 ml) was added in portions and the heating was continued for 6 h. Water (20 ml) was added and the reaction mixture was allowed to stand at room temperature overnight. The orange colored solid was filtered off, washed with water and dried under vacuum to afford 3-(1-methylindol-3-yl)-4-(3-nitrophenyl)-1H-pyrrole-2,5-dione (6.7 g, 75%).

Step 4

To a solution of 3-(1-methylindol-3-yl)-4-(3-nitrophenyl)-1H-pyrrole-2,5-dione (6.5 g, 19 mmol) in acetone (500 ml), was added TiCl_3 (45 ml) in 5 portions at 30 minute intervals. The reaction mixture was stirred at room temperature overnight and then neutralized with 10N NaOH. The product was extracted with EtOAc, dried, and concentrated. The crude product was purified on a silica gel column with 3%MeOH in CH_2Cl_2 to afford 3-(1-methylindol-3-yl)-4-(3-aminophenyl)-1H-pyrrole-2,5-dione (4.9 g, 82.5%).

Step 5


A mixture of 3-(1-methylindol-3-yl)-4-(3-aminophenyl)-1H-pyrrole-2,5-dione (100 mg, 0.32 mmol) and 2,2-dimethyldioxolane-4-carboxaldehyde (0.38 mmol) (prepared as described in Kumont, von R., et al. *Helv. Chim. Acta.*, 66, 814, (1983)) in dichloromethane (12 ml) was stirred at room temperature for 10 min., and then $\text{Na}(\text{OAc})_3\text{BH}$ (120 mg, 0.57 mmol) was added. The reaction mixture was stirred overnight and then partitioned between EtOAc and H_2O . The organic layer was separated, washed with water and concentrated. The crude product was purified by preparatory TLC with 3/1 hexanes/EtOAc to give 3-(1-methylindol-3-yl)-4-[3-(2,2-dimethyldioxolan-4-ylmethylamino)phenyl]-1H-pyrrole-2,5-dione (32.6 mg, 24%).

Step 6

3-(1-Methylindol-3-yl)-4-[3-(2,2-dimethyldioxolan-4-ylmethylamino)phenyl]-1H-pyrrole-2,5-dione (30 mg) was dissolved in MeOH (5 ml) and H₂O (1 ml). Catalytic amount of *p*-toluenesulfonic acid was added and the reaction mixture was stirred at 50 °C overnight. The reaction mixture was concentrated and the residue was purified by preparatory TLC to give 3-(1-methylindol-3-yl)-4-{3-[(2(*RS*),3-dihydroxypropylamino]phenyl}-1H-pyrrole-2,5-dione (18 mg, 66%). MS(EI): M⁺ 391; M. pt. 160-163.5 °C.

Example 8


Synthesis of 3-(1-methylindol-3-yl)-4-(3-tetrahydropyran-4-ylaminophenyl)-1H-pyrrole-2,5-dione



A mixture of 3-(1-methylindol-3-yl)-4-(3-aminophenyl)-1H-pyrrole-2,5-dione (100 mg, 0.32 mmol) and tetrahydro-4H-pyran-4-one (65 mg, 0.65 mmol) in MeOH (8 ml) was stirred at room temperature for 40 min., and then NaCNBH₃ (63 mg, 1.0 mmol) was added. After stirring the reaction mixture overnight the volatiles were removed under *vacuo* and the residue was purified by preparatory TLC (3%MeOH/CH₂Cl₂) to give 3-(1-methylindol-3-yl)-4-(3-tetrahydropyran-4-ylaminophenyl)-1H-pyrrole-2,5-dione (88.2 mg, 70%). LC/MS: M⁺ 401(98.6%).

Example 9

Synthesis of 3-(1-methylindol-3-yl)-4-[3-(2,2-dimethyl-1,3-dioxan-5-ylamino)phenyl]-1H-pyrrole-2,5-dione




5

A mixture of 3-(1-methylindol-3-yl)-4-(3-aminophenyl)-1H-pyrrole-2,5-dione (200 mg, 0.63 mmol) and 2,2-dimethyl-1,3-dioxane-5-one (98 mg, 0.76 mmol) in MeOH (10 ml) was stirred at room temperature for 15 min., and then NaCNBH₃ (79 mg, 1.26 mmol) was added. After stirring the reaction mixture overnight the volatiles were removed under *vacuo* and the residue was purified by preparatory TLC (1% MeOH/CH₂Cl₂) to give 3-(1-methylindol-3-yl)-4-[3-(2,2-dimethyl-1,3-dioxan-5-ylamino)phenyl]-1H-pyrrole-2,5-dione (185 mg, 68%). MS(EI): M⁺ 431; M. pt. 201-203 °C.

15

Example 10

Synthesis of 3-(1-methylindol-3-yl)-4-[3-(1-(*RS*)-hydroxy-2-hydroxymethylethylamino)phenyl]-1H-pyrrole-2,5-dione




20

A solution of 3-(1-methylindol-3-yl)-4-[3-(2,2-dimethyl-1,3-dioxan-5-yl-amino)phenyl]-1H-pyrrole-2,5-dione (173 mg, 0.4 mmol) in MeOH (30 ml) and H₂O (3 ml) with catalytic amount of *p*-toluenesulfonic acid was stirred at 50 °C overnight. The volatiles were removed under *vacuo* and the residue was purified by preparatory TLC (3% MeOH/CH₂Cl₂) to afford 3-(1-methylindol-3-yl)-4-[3-(1-(*RS*)-hydroxy-2-hydroxymethylethylamino)phenyl]-1H-pyrrole-2,5-dione (130 mg, 83%). MS(LSIMS): (M+H)⁺ 392, M. pt. 97.5-101 °C.


Example 11

Synthesis of 3-(1-methylindol-3-yl)-4-[3-(imidazol-2-ylmethylamino)phenyl]-1H-pyrrole-2,5-dione



A mixture of 3-(1-methylindol-3-yl)-4-(3-aminophenyl)-1H-pyrrole-2,5-dione (100 mg, 0.32 mmol) and imidazole-2-carboxaldehyde (40 mg, 0.42 mmol) in MeOH (8 ml) was stirred for 15 min., and then NaCNBH₃ (40.2 mg, 0.64 mmol) was added. After stirring the reaction mixture overnight the volatiles were removed under *vacuo* and the residue was purified by preparatory TLC (3% MeOH/CH₂Cl₂) to afford 3-(1-methylindol-3-yl)-4-[3-(imidazol-2-ylmethylamino)phenyl]-1H-pyrrole-2,5-dione (24.8 mg, 20 %). LC/MS: M⁺ 397(94.2%).

Example 12

Synthesis of 3-(1-methylindol-3-yl)-4-[3-(3-*tert*-butyldimethylsilyloxypropyl-amino)phenyl]-1H-pyrrole-2,5-dioneStep 1

Tetrapropylammonium perruthenate (0.18 g, 5.3 mmol) was added to a mixture of methylene chloride (20 ml) and acetonitrile (2 ml) containing 3-(*tert*-butyldimethylsilyloxy)-propanol (2 g, 0.01 mmol), N-methylmorpholine N-oxide (1.76 g) and 4 Å molecular sieves. The reaction mixture was stirred at RT overnight and then filtered through a pad of silica gel. The filtrate was concentrated under *vacuo* to afford 3-(*tert*-butyldimethylsilyloxy)-propionaldehyde (1.3 g, 66%).

Step 2


A mixture of 3-(1-methylindol-3-yl)-4-(3-aminophenyl)-1H-pyrrole-2,5-dione (0.2 g, 6 mmol) and 3-(*tert*-butyldimethylsilyloxy)propionaldehyde (0.25 g, 13 mmol) in CH₂Cl₂ (10 ml) and MeOH (5 ml) was stirred at room temperature for 15 min and then NaCNBH₃ (57 mg, 1.5 eq) was added. The reaction mixture was stirred at RT overnight and then concentrated under *vacuo*. The residue was purified by preparatory TLC to give 98 mg 3-(1-methylindol-3-yl)-4-[3-(3-*tert*-butyldimethylsilyloxypropylamino)phenyl]-1H-pyrrole-2,5-dione (32%) MS (LSIMS): (M+H)⁺ 490; M. pt. 58-65 °C.

Proceeding as described in example 12 above, but substituting 3-(*tert*-butyldimethyl-silyloxy)propanol with 2-(*tert*-butyldiphenylsilyloxy)ethanol

provided 3-(1-methylindol-3-yl)-4-[3-(3-*tert*-butyldiphenylsilyloxyethylamino)phenyl]-1H-pyrrole-2,5-dione.

Example 13

5 Synthesis of 3-(1-methylindol-3-yl)-4-[3-(3-hydroxypropylamino)phenyl]-1H-pyrrole-2,5-dione




10 To a solution of 3-(1-methylindol-3-yl)-4-[3-(3-*tert*-butylsilyloxypropylamino)-phenyl]-1H-pyrrole-2,5-dione (85 mg, 0.17 mmol) in THF (3 ml) was added a solution of 1 M tetrabutylammonium fluoride in THF (5 ml) via a syringe. The reaction mixture was stirred at room temperature for 1 h and then concentrated in *vacuo*. The residue was purified by preparatory TLC (4% MeOH/CH₂Cl₂) to give 3-(1-methylindol-3-yl)-4-[3-hydroxypropylamino)phenyl]-1H-pyrrole-2,5-dione which was converted to HCl salt (29 mg, 41%) by dissolving it in MeOH and adding 1M HCl in ether (3 ml).
15 MS(LSIMS): (M+H)⁺ 376, M. pt. 180-192 °C.

20 Proceeding as described in example 13 above, but substituting 3-(1-methylindol-3-yl)-4-[3-(3-*tert*-butylsilyloxypropylamino)-phenyl]-1H-pyrrole-2,5-dione with 3-(1-methylindol-3-yl)-4-[3-(3-*tert*-butyldiphenylsilyloxyethylamino)-phenyl]-1H-pyrrole-2,5-dione provided 3-(1-methylindol-3-yl)-4-[3-(2-hydroxyethylamino)phenyl]-1H-pyrrole-2,5-dione. MS(LSIMS): (M+H)⁺ 362, M. pt. 170.3-170.6 °C.
25

Example 14

Synthesis of 3-(1-methylindol-3-yl)-4-[3-(3-hydroxy-1-methylpropyl-amino)phenyl]-1H-pyrrole-2,5-dione



5


To a mixture of 3-(1-methylindol-3-yl)-4-(3-aminophenyl)-1H-pyrrole-2,5-dione (0.2 g, 0.6 mmol) and 4-hydroxy-2-butanone (80 mg, 1.5 eq) in dichloromethane (15 ml) was added NaCNBH_3 (56 mg, 1.5 eq) and the reaction mixture was stirred at RT for three days. The product 3-(1-methylindol-3-yl)-4-[3-(3-hydroxy-1-methylpropylamino)phenyl]-1H-pyrrole-2,5-dione was separated by preparatory TLC (8.9 mg, 3.6%). LC/MS: M^+ 389.

10

Example 15

Synthesis of 3-(1-methylindol-3-yl)-4-[3-(2-hydroxy-1-methylethylamino)phenyl]-1H-pyrrole-2,5-dione

15




20

To a mixture of 3-(1-methylindol-3-yl)-4-(3-aminophenyl)-1H-pyrrole-2,5-dione (100 mg, 0.32 mmol) and hydroxyacetone (0.03 ml, 1.5 eq) in CH_2Cl_2 (12 ml) and THF (5 ml) was added NaCNBH_3 (28 mg, 1.5 eq) and the reaction mixture was stirred overnight.

The volatiles were removed under *vacuo* and the residue was purified by preparatory TLC to give 3-(1-methylindol-3-yl)-4-[3-(2-hydroxy-1-methylethylamino)phenyl]-1H-pyrrole-2,5-dione (8 mg). LC/MS: M^+ 375(85.6%).

Example 16

Synthesis of 3-(1-methyl-5-chloroindol-3-yl)-4-{3-[(*RS*)-2,3-dihydroxypropylamino]phenyl}-1H-pyrrole-2,5-dione



Step 1

To a room temperature solution of 5-chloroindole (4.97 g) in dry DMF (40 ml) was added potassium hydroxide pellets (2.76 g) and stirred 1 h until most of the solid dissolved. The resulting mixture was cooled to 0 °C in an ice bath and iodomethane (2.45 ml) was added dropwise and later stirred overnight at room temperature under argon. The reaction mixture was poured into water and extracted twice with ETOAc. The ETOAc portions were combined, washed with water, dried over magnesium sulfate, concentrated, and flash chromatographed with 10%ETOAc/Hexane to give 1-methyl-5-chloroindole as a pink liquid (5.43 g).

Step 2

1-Methyl-5-chloroindole-3-glyoxylyl chloride was prepared by proceeding as described in Example 12, Step 1, but substituting 1-methyl-5-chloroindole for 1-methylindole.

Step 3

3-(1-Methyl-5-chloroindol-3-yl)-4-(3-nitrophenyl)furan-2,5-dione was prepared by proceeding as described in Example 12, Step 2, but substituting 1-

methyl-5-chloroindole-3-glyoxyl chloride for 1-methylindole-3-glyoxyl chloride.

Step 4

5 3-(1-Methyl-5-chloroindol-3-yl)-4-(3-nitrophenyl)-1H-pyrrole-2,5-dione was prepared by proceeding as described in Example 12, Step 3, but substituting 3-(1-methyl-5-chloroindol-3-yl)-4-(3-nitrophenyl)furan-2,5-dione for 3-(1-methylindol-3-yl)-4-(3-nitrophenyl)furan-2,5-dione.

10 Step 5


A mixture of 3-(1-methyl-5-chloroindol-3-yl)-4-(3-nitrophenyl)-1H-pyrrole-2,5-dione (865 mg), 10% palladium on carbon (90 mg), and glacial HOAc (35 ml) was stirred and hydrogenated at atmospheric pressure using a balloon (2 h). The reaction mixture was filtered through a pad of celite, cooled to 0 °C and KOH pellets were added until pH 8. The solution was extracted with ETOAc, dried (magnesium sulfate), and stripped. The crude was flash chromatographed with 10% through 20% ETOAc-Hexane to provide 3-(1-methyl-5-chloroindol-3-yl)-4-(3-aminophenyl)-1H-pyrrole-2,5-dione (495 mg).

20 Step 6

To a room temperature solution of 3-(1-methyl-5-chloroindol-3-yl)-4-(3-aminophenyl)-1H-pyrrole-2,5-dione (492 mg) in methanol (250 ml) was added DL-glyceraldehyde dimer dissolved in water (15 ml) followed by sodium cyanoborohydride (110 mg) and the reaction mixture was stirred overnight under argon. The reaction appeared to be only 30% complete by TLC. Additional dimer (150 mg) and cyanoborohydride (100 mg) were added. After another 6 h, the reaction appeared to be 50% complete. The solvent was removed and the crude residue was flash chromatographed with 5% to 7% to 10% MeOH/dichloromethane. 3-(1-Methyl-5-chloroindol-3-yl)-4-{3-[[((RS)-2,3-dihydroxypropyl-amino]phenyl)}-1H-pyrrole-2,5-dione was obtained as a dark red solid (220 mg). MS(EI): (M+H)⁺ 426; M. pt. 224.8-226.1 °C.

Example 17

Synthesis of 3-(1-methyl-5-fluoroindol-3-yl)-4-{3-[[*(RS)*-2,3-dihydroxypropylamino]phenyl]-1H-pyrrole-2,5-dione

Step 1

1-Methyl-5-fluoroindole was prepared by proceeding as described in Example 16, Step 1, but substituting 5-fluoroindole for 5-chloroindole.

Step 2

1-Methyl-5-fluoroindole-3-glyoxylyl chloride was prepared by proceeding as described in Example 16, Step 2, but substituting 1-methyl-5-fluoroindole for 1-methyl-chloroindole.

Step 3

3-(1-Methyl-5-fluoroindol-3-yl)-4-(3-nitrophenyl)furan-2,5-dione was prepared by proceeding as described in Example 16, Step 3, but substituting 1-methyl-5-fluoroindole-3-glyoxylyl chloride for 1-methyl-5-chloroindole-3-glyoxylyl chloride.

Step 4

3-(1-Methyl-5-fluoroindol-3-yl)-4-(3-nitrophenyl)-1H-pyrrole-2,5-dione was prepared by proceeding as described in Example 16, Step 3, but substituting 3-(1-methyl-5-fluoroindol-3-yl)-4-(3-nitrophenyl)furan-2,5-dione for 3-(1-methyl-5-chloroindol-3-yl)-4-(3-nitrophenyl)furan-2,5-dione.

Step 5


3-(1-Methyl-5-fluoroindol-3-yl)-4-(3-aminophenyl)-1H-pyrrole-2,5-dione was prepared by proceeding as described in Example 16, Step 5, but substituting 3-(1-methyl-5-fluoroindol-3-yl)-4-(3-nitrophenyl)-1H-pyrrole-2,5-dione for 1-methyl-5-chloroindol-3-yl)-4-(3-nitrophenyl)-1H-pyrrole-2,5-dione.

Step 6

3-(1-methyl-5-fluoroindol-3-yl)-4-{3-[(*RS*)-2,3-dihydroxypropylamino]phenyl}-1H-pyrrole-2,5-dione was prepared by proceeding as described in Example 16, Step 5, but substituting 3-(1-methyl-5-fluoroindol-3-yl)-4-(3-aminophenyl)-1H-pyrrole-2,5-dione for 3-(1-methyl-5-chloroindol-3-yl)-4-(3-aminophenyl)-1H-pyrrole-2,5-dione. MS(EI) ($M+H$)⁺ 410; M. pt. 223.2-225°C.

Example 18

Synthesis of 3-(1-methylindol-3-yl)-4-[3-((*R*)-2,2-dimethyl-1,3-dioxolan-4-ylmethylsulfanyl)phenyl]-1H-pyrrole-2,5-dione

Step 1

To a cold methanol (20 ml) at 0 °C was added thionyl chloride (7 ml) dropwise. After the completion of the addition, the reaction mixture was stirred at 0 °C for 10 min, and was then added 3-mercaptophenylacetic acid (4.0 g, 23.8 mmol). The resulting mixture was stirred at room temperature overnight. Volatiles were removed and the residue was partitioned between water and ethyl acetate. The organic layer was separated, washed with H₂O, NaHCO₃, and NaCl (sat.) and dried over Na₂SO₄. The crude product was purified on a silica gel column with

20% EtOAc in hexane to give bis(3-ethoxycarbonylmethylphenyl)-disulfide (4.1 g).

Step 2

5 To a solution of bis(3-methoxycarbonylmethylphenyl)disulfide (4.1 g, 11 mmol) in THF (20 ml) and methanol (5 ml) was added NaBH₄ (1.76 g, 4 eq.) and the resulting mixture was stirred at RT overnight. It was then quenched with NH₄Cl (sat.) and extracted with EtOAc. The EtOAc layer was washed with water, NaCl (sat.) and dried over Na₂SO₄. Column purification with 15% EtOAc in hexane
10 gave 3.47 g of methyl (3-mercaptophenyl)acetate (84%).

Step 3

To a solution of methyl (3-mercaptophenyl)acetate (3.47 g, 19 mmol) in N-methylpyrrolidinone (100 ml) were added (*R*)-2,2-dimethyl-1,3-dioxolan-4-ylmethyl p-tosylate) (6.54 g, 1.2 eq.) and K₂CO₃ (7.9 g, 4 eq.). The reaction
15 mixture was heated at 65 °C overnight. It was cooled to room temperature, quenched with water and extracted with EtOAc. The organic layer was separated, washed with water and NaCl (sat.), and dried over Na₂SO₄. The crude product was purified on a silica gel column with 10% EtOAc in hexane to give 5.2 g of methyl
20 3-(*R*)-2,2-dimethyl-1,3-dioxolan-4-ylmethylsulfanyl)phenylacetate (92%).

Step 4


Oxalyl chloride (1.05 eq., 3.64 ml) was added dropwise to a solution of N-methylindole (5.1 ml, 50 mmol) in diethyl ether (395 ml) at 0 °C. Yellow
25 precipitates were formed. After the completion of the addition, the reaction mixture was stirred at 0 °C for 30 min. The suspension was then dropwise added to a solution of 100 ml of ammonium hydroxide at 0 °C. White precipitate was formed and the reaction mixture was stirred at 0 °C for 10 min., after the completion of addition. Dichloromethane was added to extract and the organic
30 layer was separated, washed with NaCl (sat.), dried over sodium sulfate and concentrated. The residue was recrystallized from dichloromethane and hexane to give 5.6 g of N-methylindolyl-3-glyoxylamide.

Step 5

To a solution of N-methylindolyl-3-glyoxylamide (0.404 g, 2 mmol) in THF (15 ml) at 0° C was added potassium *tert*-butoxide (2 ml, 1.0 M in THF) dropwise. Precipitate was formed and the reaction mixture was stirred at 0 °C for 5 min. Methyl 3-(*R*)-2,2-dimethyl-1,3-dioxolan-4-ylmethylsulfanyl)phenylacetate (0.65 g, 1.1 eq.) was then added, stirred for 5 min., and was followed by the addition of potassium *tert*-butoxide (4 ml, 1.0 M). The resulting mixture was stirred at 0 °C for 2 hours and was allowed to warm to room temperature. After 3 hours, methyl 3-(*R*)-2,2-dimethyl-1,3-dioxolan-4-ylmethylsulfanyl)phenylacetate (0.65 g) was added and the reaction mixture was stirred at room temperature overnight. It was then quenched with ammonium chloride (sat.) and extracted with EtOAc. The organic layer was washed with NaCl (sat.), dried and concentrated. Column purification with 7/43/50 of EtOAc/CH₂Cl₂/hexanes gave 0.52 g of 3-(1-methylindol-3-yl)-4-[3-(*R*)-2,2-dimethyl-1,3-dioxolan-4-ylmethylsulfanyl)-phenyl]-1H-pyrrole-2,5-dione. MS(EI): M⁺ 448.

Example 19

Synthesis of 3-(1-methylindol-3-yl)-4-[3-(*R*)-2,2-dimethyl-1,3-dioxolan-4-ylmethylsulfanyl)phenyl]-1H-pyrrole-2,5-dione



20


To a solution of 3-(1-methylindol-3-yl)-4-[3-(*R*)-2,2-dimethyl-1,3-dioxolan-4-ylmethylsulfanyl)phenyl]-1H-pyrrole-2,5-dione (100 mg, 0.22 mmol) in methanol (5 ml) and water (2.5 ml) at -10 °C was added oxone (16 mg, 1.15 eq.) and stirred for 2 hours at -10 °C. The reaction mixture was then poured into ice water and extracted with dichloromethane. The organic layer was washed with NaS₂O₃ (15% aq.), NaCl (sat.) and dried over sodium sulfate. Preparative TLC with 2/4/4 of acetone/dichloromethane/hexane gave 45 mg of 3-(1-methylindol-3-yl)-4-

25

[3-((*R*)-2,2-dimethyl-1,3-dioxolan-4-ylmethylsulfinyl)phenyl]-1H-pyrrole-2,5-dione. MS (ESI): (M+1)⁺ 465.

Example 20


5 Synthesis of 3-(1-methylindol-3-yl)-4-[3-((*R*)-2,2-dimethyl-1,3-dioxolan-4-ylmethylsulfonyl)phenyl]-1H-pyrrole-2,5-dione



10 To a solution of 3-(1-methylindol-3-yl)-4-[3-((*R*)-2,2-dimethyl-1,3-dioxolan-4-ylmethylsulfonyl)phenyl]-1H-pyrrole-2,5-dione (100 mg, 0.22 mmol) in methanol (20 ml) and water (5 ml) was added oxone in 5 ml of water at 0 °C. The resulting suspension was stirred at 0 °C for 30 min., and was allowed to warm to room temperature and stirred for 5 hours. The reaction mixture was then poured into ice water and extracted with dichloromethane. The organic layer was washed
15 with NaS₂O₃ (15% aq.), NaCl (sat.) and dried over sodium sulfate. Preparative TLC with 2/4/4 of acetone/dichloromethane/hexane gave 40 mg of 3-(1-methylindol-3-yl)-4-[3-((*R*)-2,2-dimethyl-1,3-dioxolan-4-ylmethylsulfonyl)phenyl]-1H-pyrrole-2,5-dione. MS (ESI): (M+1)⁺ 481.

Example 21

Synthesis of 3-(1-methylindol-3-yl)-4-[3-((*R*)-2,3-dihydroxypropylsulfanyl)phenyl]-1H-pyrrole-2,5-dione



5

Toluenesulfonic acid (10 mg) was added to a solution of 3-(1-methylindol-3-yl)-4-{3-((*R*)-2,2-dimethyl-1,3-dioxolan-4-ylmethylsulfanyl)phenyl}-1H-pyrrole-2,5-dione (60 mg) in methanol (10 ml) and water (1 ml) and the reaction mixture was heated at 50 °C for 2 hours. The volatiles were removed and the residue was partitioned between water and EtOAc. The organic layer was washed with NaCl (sat.) and dried over sodium sulfate. The crude product was purified on a silica gel column with 10/45/45 of MeOH/CH₂Cl₂/hexane and further purified by recrystallization from CH₂Cl₂/hexane to give 3-(1-methylindol-3-yl)-4-[3-((*R*)-2,3-dihydroxypropylsulfanyl)phenyl]-1H-pyrrole-2,5-dione (47 mg). MS (EI): M⁺ 408.

15

Following the procedure described above but substituting 3-(1-methylindol-3-yl)-4-{3-((*R*)-2,2-dimethyl-1,3-dioxolan-4-ylmethylsulfanyl)phenyl}-1H-pyrrole-2,5-dione with 3-(1-methylindol-3-yl)-4-{3-((*R*)-2,2-dimethyl-1,3-dioxolan-4-ylmethylsulfinyl)phenyl}-1H-pyrrole-2,5-dione gave 3-(1-methylindol-3-yl)-4-[3-((*R*)-2,3-dihydroxypropylsulfinyl)-phenyl]-1H-pyrrole-2,5-dione. MS (ESI): (M+1)⁺ 425.

20


Following the procedure described above but substituting 3-(1-methylindol-3-yl)-4-{3-((*R*)-2,2-dimethyl-1,3-dioxolan-4-ylmethylsulfanyl)phenyl}-1H-pyrrole-2,5-dione with 3-(1-methylindol-3-yl)-4-{3-((*R*)-2,2-dimethyl-1,3-dioxolan-4-ylmethylsulfonyl)phenyl}-1H-pyrrole-2,5-dione gave 3-(1-methylindol-3-yl)-4-[3-

25

((*R*)-2,3-dihydroxypropylsulfonyl)-phenyl]-1H-pyrrole-2,5-dione. MS (ESI): (M+1)⁺ 441.

Example 22

5 Synthesis of 3-{3-[(2,3-dihydroxypropyl)amino]phenyl}-4-[5-fluoro-1-(3-hydroxypropyl)-1*H*-indol-3-yl]-1*H*-pyrrole-2,5-dione



Step 1

10 Chlorotriphenylmethane (14.64 g, 52.5 mmol) was added at once to a solution of 3-bromo-1-propanol (6.95 g, 62.5 mmol) in pyridine (30 ml) under argon. The solution was stirred under argon for 12 hours and a precipitate formed. It was filtered and washed with pyridine. The filtrate was stripped and combined with the previous precipitate. This substance was purified *via* column chromatography (SiO₂, 5% CH₂Cl₂ / Hexane then 10% CH₂Cl₂ / Hexane). The colorless oil (5.2 g) was allowed to solidify and was recrystallized from hexane to provide the protected alcohol (5.2 g).

Step 2

20 To a solution of sodium hydride (60%, 0.44 g, 10.9 mmol) in dimethylformamide (8 ml) under argon at room temperature was added 5-fluoroindole (0.98 g, 7.25 mmol) in dimethylformamide (10 ml). The resultant solution was stirred for 1 hour and then cooled to 0 °C. The bromide (Step 1-above, 4.15 g, 10.9 mmol) in dimethylformamide (15 ml) was added and the reaction was allowed to come to room temperature and stir for 12 hours. The mixture was poured in water (200 ml) and extracted with ethyl acetate (2X). The organic solution was washed with water (2X) and dried (brine, MgSO₄).
25 Evaporation under reduced pressure provided a colorless oil (4.9 g) which was

purified through chromatography (SiO_2 , 5% ETOAc-Hexane) yielding the indole as a white solid (2.98 g).

Step 3

5 The alkylated fluoroindole (Step 2 – above) was converted to the nitroaryl indole through procedures previously described in Example 7, steps 1-3.

Step 4

10 A suspension of nitroaryl indole (Step 3 – above, 0.7 g, 10.7 mmol), triirondodecacarbonyl (0.65 g, 1.3 mmol), and absolute ethanol (30 ml) was refluxed overnight under argon. The hot mixture was filtered through a Buchner funnel packed tightly with celite and washed several times with hot methanol and hot 50% MeOH / EtOAc until most of the orange color was removed. Evaporation of the volatiles under reduced pressure and purification *via* chromatography (SiO_2 , 15 CH_2Cl_2 , then 1% MeOH / CH_2Cl_2 , then 2% MeOH / CH_2Cl_2) yielded the aniline as an orange solid (0.43 g).

Step 5

20 DL-glyceraldehyde(0.25 g, 1.38 mmol) in water (30 ml) was added to a solution of the aniline (Step 4 – above, 0.43 g, 0.69 mmol) in MeOH (completely dissolved) under argon. The reaction was stirred for 30 minutes, sodium cyanoborohydride (89 mg, 1.38 mmol) was added and the mixture was stirred for 12 hours. Evaporation under reduced pressure and purification through chromatography (SiO_2 , 5% MeOH / CH_2Cl_2 / 0.5% NH_4OH) provided the diol as 25 an orange foam (295 mg).

Step 6


30 To a room temperature solution of the diol (Step 5 – above, 0.245 g, 0.35 mmol) in methylene chloride (10 ml) under argon was added trifluoroacetic acid (0.16 ml, 2.22 mmol) followed by trifluoroacetic anhydride (0.3 ml, 2.11 mmol). The reaction was stirred for 10 minutes, cooled to 0 °C and triethylamine (0.6 ml) was added. The solution was stirred for 15 minutes, water (0.5 ml) was added and the reaction was poured into MeOH (10 ml). Evaporation of the volatiles under reduced pressure yielded a crude reaction residue. This was

dissolved in methylene chloride, washed with brine (5%) and evaporated *in vacuo*. The resultant material was dissolved in methylene chloride/methanol (50%) and treated with triethylamine. (1-2 mls) and evaporated under reduced pressure. Purification *via* chromatography (SiO₂, CH₂Cl₂ then 5% MeOH/ CH₂Cl₂) provided the free base. Addition of hydrochloric acid in ether (1M, 2 eq.) followed by removal of the volatiles yielded 3-{3-[(2,3-dihydroxypropyl)amino]phenyl}-4-[5-fluoro-1-(3-hydroxypropyl)-1*H*-indol-3-yl]-1*H*-pyrrole-2,5-dione (94 mg). M. pt. 118-125 °C; MS(EI): (M+H)⁺ 454.

10

Example 23

Synthesis of 3-(5-fluoro-1-methyl-1*H*-indol-3-yl)-4-[3-(4-hydroxypiperidin-1-yl)phenyl]-1*H*-pyrrole-2,5-dione

Step 1

To a room temperature solution of 3-bromophenethyl alcohol (1.22 g, 6.05 mmoles) in methylene chloride (20 ml) and dihydrofuran (2.54 g, 30.3 mmoles) was added *p*-toluenesulfonic acid monohydrate (11.5 mg, 0.06 mmoles). The reaction was stirred for 30 minutes followed by the addition of ether (50 ml). The organic solution was washed with saturated aqueous sodium bicarbonate solution (50 ml), dried (MgSO₄), and evaporated under reduced pressure to an oil (3.5 g). This was purified *via* flash chromatography (SiO₂, 4% EtOAc /Hexane) providing 2-[2-(3-bromophenyl)ethoxy]tetrahydro-2*H*-pyran, as a colorless liquid (1.4 g).

Step 2

The tetrahydropyran (Step 1- above, 0.40 g, 1.97 mmoles), BINAP (90 mg, 0.295 mmoles), Pd₂(dba)₃ (90 mg, 0.0486 mmoles), anhydrous sodium *t*-butoxide (0.28 g) were suspended in toluene (20 ml) under argon. 4-[[*tert*-butyl(diphenyl)silyl]oxy]piperidine (0.67 g, 1.97 mmoles) was then added and the reaction was stirred at 100 °C for 12 hours. After cooling to room temperature,

ether (50 ml) was added; the reaction mixture was filtered through celite and washed with additional ether (25 ml). Evaporation under reduced pressure and purification through chromatography (SiO₂, 5% to 7% EtOAc / Hexane) yielded 4-
5 {*tert*-butyl(diphenyl)silyl}oxy}-1-{3-[2-(tetrahydro-2*H*-pyran-2-yloxy)ethyl]phenyl} piperidine as a tan oil (0.674 g, 1.24 mmol).

Step 3

A solution of the piperidine (Step 2 – above, 0.64 g, 1.18 mmol) in acetic acid/tetrahydrofuran/water (4:2:1) was stirred under argon at 50 °C for 24 hours.
10 After removal of the volatiles *via* evaporation, toluene was added and the reaction was evaporated a second time. Purification *via* flash chromatography (SiO₂, 10% EtOAc / Hexane) yielded the primary alcohol (0.42 g, 0.914 mmol).

Step 4

15 To a 0 °C solution of the alcohol (Step 3 – above, 0.42 g, 0.914 mmol) in acetone (6 ml) was added Jones Reagent (1.9 M, 1.05 ml) dropwise. The solution was stirred at 0 °C for 1 hour, warmed to room temperature and allowed to stir for an additional 2 hours. Isopropanol (10 ml) was added dropwise, the reaction was filtered through celite and washed with acetone (40 ml). The filtrate was
20 evaporated under reduced pressure, water was added and the mixture was extracted with ethyl acetate (2X). The organic solution was dried (brine, MgSO₄), and evaporated *in vacuo* to provide the carboxylic acid as a solid (100 mg, 0.21 mmol).

Step 5

25 To a room temperature solution of the acid (Step 4 – above, 100 mg, 0.21 mmol) in methylene chloride (5 ml) under argon was added oxalyl chloride (22 µl) dropwise. The reaction was stirred for 2 hours, cooled to 0 °C and ammonia hydroxide (0.5 ml) was added dropwise. The mixture was stirred at room
30 temperature for 1 hour and evaporated under reduced pressure. The crude mixture was dissolved in methylene chloride, filtered and evaporated *in vacuo* to yield the amide (94.5 mg, 0.2 mmol).

Step 6

To a 0 °C solution of 1-methylindole (7.58 g, 50 mmol) in dry ether (75 ml) under argon was added oxalyl chloride (4.36 ml, 50 mmol) slowly. The resulting suspension was stirred for 30 minutes. After cooling to -65 °C, sodium methoxide (22.9 ml, 100 mmol, 25% in MeOH) was added dropwise at a rate to maintain -60 °C. After the addition was complete, the reaction was allowed to warm to room temperature and stir for 2 hours. Water was added (30 ml) and the crude mixture was stirred then filtered. The resultant solid was washed with water, ether and then air dried. Purification of the crude product *via* flash chromatography (SiO₂, 20% to 40% ethyl acetate/Hexane – gradient) provided methyl (1-methyl-1*H*-indol-3-yl)(oxo)acetate as a solid (9 g, 41.4 mmol).


Step 7

To a 0 °C solution of methyl (1-methyl-1*H*-indol-3-yl)(oxo)acetate (Step 6 – above, 51.3 mg, 0.237 mmol) and 2-[3-(4-[[*tert*-butyl(diphenyl)silyl]oxy]piperidin-1-yl)phenyl]acetamide (Step 5 – above, 93.3 mg, 0.197 mmol) in tetrahydrofuran (10 ml) was added dropwise a solution of potassium *t*-butoxide (0.59 ml, 0.591 mmol, 1 M in THF). The reaction was stirred at room temperature for 12 hours. Water was added to the suspension and the mixture was extracted with ether (2X), dried (brine, MgSO₄). Evaporation of the volatiles under reduced pressure and purification *via* flash chromatography (SiO₂, 1% MeOH / CH₂Cl₂) provided the indole (54 mg, 0.084 mmol).

Step 8

To a room temperature solution of the indole (Step 7 – above, 52 mg, 0.0812 mmol) in dry tetrahydrofuran (3 ml) under argon was added tetrabutylammonium fluoride (0.122 ml, 0.122 mmol, 1 M in THF). The reaction was stirred for 12 hours and then water (25 ml) was added. The mixture was extracted with ethyl acetate (2X), dried (brine, MgSO₄), and evaporated *in vacuo*. Purification of the resultant product *via* flash chromatography (SiO₂, 4% MeOH / CH₂Cl₂) provided 3-[3-(4-hydroxypiperidin-1-yl)phenyl]-4-(1-methyl-1*H*-indol-3-yl)-1*H*-pyrrole-2,5-dione as a powder (29.9 mg, 0.0745 mmol); M. pt. 136-141 °C; MS(EI): (M+H)⁺ 402.


Example 24



Following the procedure described in examples 1 and 2, but substituting N-methylindole with N-methyl-5-chloroindole and N-methyl-5-fluoroindole in step 4 of example 1 gave 3-(1-methyl-5-chloroindol-3-yl)-4-{3-[(R)-2-hydroxy-2-hydroxymethyl]ethoxy}phenyl}-1H-pyrrole-2,5-dione (MS (EI): (M+H)⁺ 427); and 3-(1-methyl-5-fluoroindol-3-yl)-4-{3-[(R)-2-hydroxy-2-hydroxymethyl]ethoxy}phenyl}-1H-pyrrole-2,5-dione (MS (EI): (M+H)⁺ 411), respectively.

Example 25

Synthesis of 3-(5-methoxy-1-methylindol-3-yl)-4-{3-[(2,3-dihydroxypropyl)amino]phenyl}-1H-pyrrole-2,5-dione

Step 1

A mixture of 5-methoxyindole-2-carboxylic Acid (6 g, 31.4 mmol) and basic copper(II) carbonate(0.6 g) was heated to 230 °C-240 °C under N₂ for five to six hours. After cooling, the resulting black gum was treated with benzene and filtered. The filtrate was concentrated and purified by flash column with 9/1

Hex/EtOAc then with 6/1 Hexane/EtOAc. The desired product, 5-methoxyindole (3.1 g) was obtained (61.6%). MS (EI): ($M^+ + 1$) 148.

Step 2

5 To a solution of 5-methoxyindole (1 g, 6.8 mmol) in 8 ml of DMF were added potassium hydroxide (0.92 g, 2.4 eq.) and methyl iodide (1 ml, 16 mmol). The resulting mixture was stirred at room temperature overnight. After removing volatile, the residue was diluted with EtOAc and washed with water (4x). The organic layer was dried and concentrated to afford 0.9 g (82%) 5-methoxy-1-methylindole. MS (EI): ($M^+ + 1$) 162.

Step 3

3-(5-methoxy-1-methylindol-3-yl)-4-(3-nitrophenyl)furan-2,5-dione was prepared by proceeding as described in Example 7, step 1 and 2, but substituting 5-methoxy-1-methylindole for 1-methylindole.

Step 4

3-(5-methoxy-1-methylindol-3-yl)-4-(3-nitrophenyl)-1H-pyrrole-2,5-dione was prepared by proceeding as described in Example 7, step 3, but substituting 3-(5-methoxy-1-methylindol-3-yl)-4-(3-nitrophenyl)furan-2,5-dione for 3-(1-methylindol-3-yl)-4-(3-nitrophenyl)furan-2,5-dione.

Step 5

3-(5-methoxy-1-methylindol-3-yl)-4-(3-aminophenyl)-1H-pyrrole-2,5-dione was prepared by proceeding as described in Example 7, step 4, but substituting 3-(5-methoxy-1-methylindol-3-yl)-4-(3-nitrophenyl)-1H-pyrrole-2,5-dione for 3-(1-methylindol-3-yl)-4-(3-nitrophenyl)-1H-pyrrole-2,5-dione.

Step 6

30 3-(5-methoxy-1-methyl-1H-indol-3-yl)-4-{3-[(2,3-dihydroxypropyl)amino]phenyl}-1H-pyrrole-2,5-dione was prepared as described in Example 7, step 5, but substituting 3-(5-methoxy-1-methylindol-3-yl)-4-(3-aminophenyl)-


1H-pyrrole-2,5-dione for 3-(1-methylindol-3-yl)-4-(3-aminophenyl)-1H-pyrrole-2,5-dione. MS (EI): M^+ 421

Following the procedure described above, but substituting 5-methylindole-2-carboxylic acid for 5-methoxyindole-2-carboxylic acid in step 1 afforded 3-(1,5-dimethyl-1H-indol-3-yl)-4-{3-[(2,3-dihydroxy-propyl)amino]phenyl}-1H-pyrrole-2,5-dione. MS (EI): M^+ 405.

Example 26

10

Synthesis of 3-(5-isopropoxy-1-methylindol-3-yl)-4-{3-[(2,3-dihydroxy-propyl)amino]phenyl}-1H-pyrrole-2,5-dione



15

Step 1

A mixture of 3-methyl-4-nitrophenol (4.59 g, 0.03 mol) and 2-bromopropane (4.06 g, 0.033 mol) was refluxed with potassium carbonate (10 g) in acetone (200 ml) for 5 hours. After cooling, the reaction mixture was filtered through celite and the residue was purified by flash column (9/1 of Hexane/EtOAc) to afford 3.42 g of 4-isopropoxy-2-methyl-1-nitrobenzene (58.5%).

20

Step 2

A mixture of 4-isopropoxy-2-methyl-1-nitrobenzene (3.55 g, 0.018 mol) and tert-butoxybis(dimethylamino)methane (9 ml) was refluxed for 4 hours and the volatile was removed. The dark brown residue was dissolved in THF (150 ml) and hydrogenated with catalytic amount of 10% Pd on Carbon with H_2 in a balloon. After stirring at room temperature overnight, the catalyst was filtered off and the

25


filtrate was concentrated to afford 3.07 g 5-isopropoxyindole (96%). MS(ED): ($M^+ + 1$) 176.

Step 3

The procedure described in Example 24, step 2 through step 6 was followed, but substituting 5-isopropoxyindole for 5-methoxyindole to provide 3-(5-isopropoxy-1-methyl-indol-3-yl)-4-{3-[(2,3-dihydroxy-propyl)amino]phenyl}-1H-pyrrole-2,5-dione. MS (ED): M^+ 449.

Example 27

Synthesis of 3-(1-methyl-indol-3-yl)-4-{3-((R)-2,3-dihydroxy-propoxyl)-2-methylphenyl}-1H-pyrrole-2,5-dione



Step 1

To a methanol solution (25 ml) at 0 °C was dropwise added thionyl chloride (9.6 ml, 0.13 mol). After 15 minutes, 3-hydroxy-2-methylbenzoic acid (4 g, 0.033 mol) was added and the resulting mixture was stirred at room temperature for 24 hours. Volatile was removed under vacuo and the residue was partitioned between water and ethyl acetate. The organic layer was separated, washed with water and saturated sodium chloride solution, and was dried over sodium sulfate. After concentration, the crude product was recrystallized from dichloromethane and hexane to give 3.48 g of methyl 3-hydroxy-2-methylbenzoate.

Step 2

To a solution of methyl 3-hydroxy-2-methylbenzoate (3.0 g, 18 mmol) in N-methylpyrrolidinone (30 ml) was added (R)-2,2-dimethyl-1,3-dioxolan-4-ylmethyl *p*-tosylate (6.2 g, 1.2 eq.), and followed by K_2CO_3 (7.5 g, 3eq.). After the

mixture was heated at 96 °C overnight, it was cooled to room temperature, quenched with H₂O, and partitioned between H₂O and EtOAc. The organic layer was separated, washed with H₂O and NaCl (sat.), and then dried over Na₂SO₄. The crude product was purified on a silica gel column with 20% EtOAc in hexane to give methyl 3-((R)-2,2-dimethyl-1,3-dioxolan-4-ylmethoxy)-2-methylbenzoate as an oil (4.5 g).

Step 3

Methyl 3-((R)-2,2-dimethyl-1,3-dioxolan-4-ylmethoxy)-2-methylbenzoate (4.2 g, 15 mmol) was dissolved in 20 ml of methanol and 1 ml of water. To the above solution was added lithium hydroxide (2.4 g, 5 eq.). After stirring the reaction mixture at room temperature for 4 hours, the volatile was removed under *vacuo* and the residue was partitioned between EtOAc and H₂O. The aqueous layer was separated, cooled with an ice bath, and then acidified with 10% aq. HCl. The acidic aqueous layer was extracted with EtOAc. The EtOAc layer was washed with NaCl (sat.), dried over Na₂SO₄, and concentrated to give 3-((R)-2,2-dimethyl-1,3-dioxolan-4-ylmethoxy)benzoic acid as a white solid (4 g).

Step 4

To a solution of 3-((R)-2,2-dimethyl-1,3-dioxolan-4-ylmethoxy)-2-methylbenzoic acid (2.4 g, 9 mmol) in 20 ml of dichloromethane was added oxalyl chloride (0.86 ml, 1.1 eq.). The resulting mixture was stirred at room temperature in the presence of a catalytic amount of DMF. Bubbles formed and stirring continued until no more bubbles were generated. Volatile was removed under *vacuo* and the residue was suspended in ether (20 ml) and was added dropwise to an ether solution (60 ml) at 0 °C containing diazomethane generated from N-nitroso-N-methylurea (6.95 g, 7.5 eq.) and 19 g of potassium hydroxide according to the procedure described by Berkowitz, D. B. in J. Org. Chem. **65**, 847, (2000). The resulting mixture was stirred at 0 °C for 1 hour and was allowed to warm to room temperature, where it was stirred for another hour. Excess amount of diazomethane was quenched with acetic acid and the volatile was removed under *vacuo*. The residue was purified on a silica gel column with 10% ethyl acetate in

hexane to give 0.8 g of 2-diazo-1-[3-((R)-2,2-dimethyl-[1,3]-dioxolan-4-ylmethoxy)-2-methyl-phenyl]ethanone.

Step 5

5 To a solution of 2-diazo-1-[3-(2,2-dimethyl-[1,3]-dioxolan-4-ylmethoxy)-2-methyl-phenyl]ethanone (0.5 g, 1.73 mmol) in 20 ml of methanol at room temperature was added dropwise a solution of silver benzoate (52 mg, 13%) in 2.6 ml of triethylamine. The solution turned greenish and then brown, black precipitate formed. After stirring for 1.5 hour, it was filtered through celite and the filtrate was
10 concentrated. The residue was then purified on a silica gel column with 20% ethyl acetate in hexane to afford 0.43 g of [3-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-2-methylphenyl] acetic acid methyl ester. The above ester was then hydrolyzed by stirring with lithium hydroxide (0.25 g) in 5 ml of methanol at room temperature to give 0.4 g of [3-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-2-methylphenyl] acetic acid.
15

Step 6

3-(1-methylindol-3-yl)-4-[3-(R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-2-methylphenyl]furan-2,5-dione was prepared according to the procedure described
20 in Example 1, step 4, but substituting [3-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-2-methylphenyl] acetic acid for 3-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)phenylacetic acid.

Step 7

25 3-(1-methylindol-3-yl)-4-[3-(R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-2-methylphenyl]-1H-pyrrole-2,5-dione was prepared according to the procedure described in Example 1, step 5, but substituting 3-(1-methylindol-3-yl)-4-[3-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy))-2-methylphenyl]furan-2,5-dione for 3-(1-methylindol-3-yl)-4-[3-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)phenyl]furan-2,5-dione.
30


Step 8

3-(1-methylindol-3-yl)-4-[3-((R)-2,3-dihydroxypropoxy)-2-methylphenyl]-1H-pyrrole-2,5-dione was prepared according to the procedure described in

Example 2, step 1, but substituting 3-(1-methylindol-3-yl)-4-[3-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-2-methylphenyl]-1H-pyrrole-2,5-dione for 3-(1-methylindol-3-yl)-4-[3-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)phenyl]-1H-pyrrole-2,5-dione. MS (EI): (M^+ +1) 407.

Example 28

Synthesis of 3-(1-methyl-indol-3-yl)-4-{3-((R)-2,3-dihydroxy-propoxyl)-2-nitrophenyl}-1H-pyrrole-2,5-dione



Step 1

To a methanol solution (15 ml) at 0 °C was dropwise added thionyl chloride (6.4 ml, 0.088 mol). After 15 minutes, 3-hydroxy-2-nitrobenzoic acid (4 g, 0.022 mol) was added and the resulting mixture was stirred at room temperature for 72 hours. Volatile was removed under vacuo and the residue was partitioned between water and ethyl acetate. The organic layer was separated, washed with water and saturated sodium chloride, and was dried over sodium sulfate. After concentration, the crude product was recrystallized from dichloromethane and hexane to give 4.5g of methyl 3-hydroxy-2-nitrobenzoate.

Step 2

To a solution of methyl 3-hydroxy-2-nitrobenzoate (1.97 g, 10 mmol) in N-methylpyrrolidinone (15 ml) was added (R)-2,2-dimethyl-1,3-dioxolan-4-ylmethyl *p*-tosylate (3.43 g, 1.2 eq.), and followed by K_2CO_3 (4.2 g, 3eq.). After the mixture was heated at 96 °C overnight, it was cooled to room temperature, quenched with H_2O , and partitioned between H_2O and EtOAc. The organic layer was separated, washed with H_2O and NaCl (sat.), and then dried over Na_2SO_4 . The crude product was purified on a silica gel column with 20% EtOAc in hexane to give methyl 3-((R)-2,2-dimethyl-1,3-dioxolan-4-ylmethoxy)-2-nitrobenzoate as an oil (3.1 g).

Step 3

Methyl 3-((*R*)-2,2-dimethyl-1,3-dioxolan-4-ylmethoxy)-2-nitrobenzoate (2.8 g, 9 mmol) was dissolved in 25 ml of methanol and 2 ml of water. To the above solution was added lithium hydroxide (1.13 g, 3 eq.). After stirring the reaction mixture at room temperature for 5 hours, the volatile was removed under *vacuo* and the residue was partitioned between EtOAc and H₂O. The aqueous layer was separated, cooled with an ice bath, and then acidified with 10% aq. HCl. The acidic aqueous layer was extracted with EtOAc. The EtOAc layer was washed with NaCl (sat.), dried over Na₂SO₄, and concentrated to give 3-((*R*)-2,2-dimethyl-1,3-dioxolan-4-ylmethoxy)-2-nitrobenzoic acid as a white solid (1.9 g).

Step 4

To a solution of 3-((*R*)-2,2-dimethyl-1,3-dioxolan-4-ylmethoxy)-2-nitrobenzoic acid (1.9 g, 6.4 mmol) in 20 ml of dichloromethane was added oxalyl chloride (0.55 ml, 1.1 eq.). The resulting suspension was stirred at room temperature in the presence of catalytic amount of DMF. Bubbles formed, and stirring continued until no more bubbles were generated while the suspension turned into a solution. Volatile was removed under *vacuo* and the residue was suspended in ether (15 ml) and was added dropwise to an ether solution (40 ml) at 0 °C containing diazomethane generated from *N*-nitroso-*N*-methylurea (4.95 g, 7.5 eq.) and 13.5 g of potassium hydroxide according to the procedure described by Berkowitz, D. B. in *J. Org. Chem.* **65**, 847, (2000). The resulting mixture was stirred at 0 °C for 1 hour and was allowed to warm to room temperature, where it was stirred overnight. Excess of diazomethane was quenched with acetic acid and the volatile was removed under *vacuo*. The residue was purified on a silica gel column with 2/4/4 of acetone/dichloromethane/hexane to give 0.95 g of 2-diazo-1-[3-((*R*)-2,2-dimethyl-[1,3]-dioxolan-4-ylmethoxy)-2-nitrophenyl]ethanone.

Step 5

To a solution of 2-diazo-1-[3-(2,2-dimethyl-[1,3]-dioxolan-4-ylmethoxy)-2-nitrophenyl]ethanone (0.9 g, 2.8 mmol) in 30 ml of methanol at room temperature was added dropwise a solution of silver benzoate (84 mg, 13%) in 4.2 ml of

triethylamine. The solution turned greenish and then brown, black precipitate formed. After stirring for 1.5 hour, it was filtered through celite and the filtrate was concentrated. The residue was then purified on a silica gel column with 20% ethyl acetate in hexane to afford 0.75 g of [3-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-2-nitrophenyl] acetic acid methyl ester. The above ester (0.52 g, 1.6 mmol) was then hydrolyzed by stirring with lithium hydroxide (0.27 g) in 5 ml of methanol at room temperature to give 0.5 g of [3-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-2-nitrophenyl] acetic acid.

10 Step 6

3-(1-methylindol-3-yl)-4-[3-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-2-nitrophenyl]furan-2,5-dione was prepared according to the procedure described in Example 1, step 4, but substituting [3-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-2-nitrophenyl] acetic acid for 3-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)phenylacetic acid.

Step 7

3-(1-methylindol-3-yl)-4-[3-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-2-nitrophenyl]-1H-pyrrole-2,5-dione was prepared according to the procedure described in Example 1, step 5, but substituting 3-(1-methylindol-3-yl)-4-[3-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy))-2-nitrophenyl]furan-2,5-dione for 3-(1-methylindol-3-yl)-4-[3-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)phenyl]furan-2,5-dione.

25 Step 8

3-(1-methylindol-3-yl)-4-[3-((R)-2,3-dihydroxypropoxy)-2-nitrophenyl]-1H-pyrrole-2,5-dione was prepared according to the procedure described in Example 2, step 1, but substituting 3-(1-methylindol-3-yl)-4-[3-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-2-nitrophenyl]-1H-pyrrole-2,5-dione for 3-(1-methylindol-3-yl)-4-[3-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)phenyl]-1H-pyrrole-2,5-dione. MS (EI): ($M^+ + 1$) 438.

Following the procedure described above, but substituting 5-hydroxy-2-nitrobenzoic acid for 3-hydroxy-2-nitrobenzoic acid gave 3-(1-methylindol-3-yl)-4-{5-((R)-2,3-dihydroxy-propoxyl)-2-nitrophenyl}-1H-pyrrole-2,5-dione. MS (EI): ($M^+ + 1$) 438.

5

The following are representative pharmaceutical formulations containing a compound of Formula (I).

Example A

Tablet formulation

10 The following ingredients are mixed intimately and pressed into single scored tablets.

	Quantity per	
	Ingredient	tablet, mg
15	compound of this invention	400
	cornstarch	50
	croscarmellose sodium	25
	lactose	120
	magnesium stearate	5

20

Example B

Capsule formulation

The following ingredients are mixed intimately and loaded into a hard-shell gelatin capsule.

25

	Quantity per	Ingredient
	capsule, mg	
	compound of this invention	200
	lactose, spray-dried	148
30	magnesium stearate	2

Example C

Suspension formulation

The following ingredients are mixed to form a suspension for oral administration.

5		Ingredient	Amount
		compound of this invention	1.0 g
		fumaric acid	0.5 g
		sodium chloride	2.0 g
10		methyl paraben	0.15 g
		propyl paraben	0.05 g
		granulated sugar	25.0 g
		sorbitol (70% solution)	13.00 g
		Veegum K (Vanderbilt Co.)	1.0 g
15		flavoring	0.035 ml
		colorings	0.5 mg
		distilled water	q.s. to 100 ml

Example D

Injectable formulation

The following ingredients are mixed to form an injectable formulation.

		Ingredient	Amount
		compound of this invention	0.2 mg-20 mg
25		sodium acetate buffer solution, 0.4 M	2.0 ml
		HCl (1N) or NaOH (1N)	q.s. to suitable
	pH	water (distilled, sterile)	q.s. to 20 ml

Example E

Suppository formulation

A suppository of total weight 2.5 g is prepared by mixing the compound of the invention with Witepsol® H-15 (triglycerides of saturated vegetable fatty acid; Riches-Nelson, Inc., New York), and has the following composition:

compound of the invention	500 mg
Witepsol® H-15	balance

Example I

Inhibition of Glycogen Synthase Kinase-3 β -- *in vitro* assay

The *in vitro* GSK-3 β inhibitory activity of compounds of this invention was determined with a truncated form of recombinant rabbit GSK-3 β enzyme.

Isolation of GSK-3 β

The construct was cloned in pGEX-3X vector according to the procedure described in Wang, Q. M. *et al.*, *J. Biol. Chem.* 269, 14566-14574 (1994). Ten amino acids at the N-terminus were deleted to obtain constitutively active GSK-3 β (see Murai H. *et al.*, *FEBS Lett.* 392,153-60, (1996)). GSK-3 β was expressed in BL21 DE3 cells. The cells were grown at 37 °C until they reached mid log phase and then induced with isopropyl-beta-(D)-thiogalactopyranoside (final concentration 0.4mM) at 30 °C for 2 h. The cells were homogenized and the cell extract was loaded on a glutathione sepharose 4B column. GSK-3 β was eluted with glutathione buffer (50 mM Tris pH 8 and 10 mM reduced glutathione). The eluate was collected in 3 minute fractions and assayed for GSK-3 β content on a 10% SDS PAGE (polyacrylamide gel electrophoresis). Fractions above 20% peak height were pooled, aliquoted, and stored at -80 °C until used.

Inhibition of GSK-3 β

The GSK-3 β binding assay was performed in 50 μ l reactions in a 96 well polypropylene plate, each reaction containing 20 mM magnesium chloride, 40 μ M

ATP, 2 mM DTT, 88.5 μ M biotinylated and phosphorylated CREB-peptide substrate (biotin-KRREILSRPS(PO₄)YR-OH, *see* Wang, Q.M. et al., *J. Biol. Chem.* 269, 14566-14574 (1994)), [γ -³³P] ATP (1 μ Ci), and 2 μ l of compounds of this invention in DMSO (various concentrations). 15 μ l of GSK-3 β (various concentrations) was added and the reaction mixture was incubated at 30 °C for 1 hour. The reaction was stopped by transferring 25 μ l of the reaction mixture to a phosphocellulose plate containing 130 μ l of 1.85% phosphoric acid. The free radionucleotides in the membrane were washed off under vacuum with 1.85% phosphoric acid (5 times). After the last wash, the plate was transferred to an
10 adoptor plate and 50 μ l of scintillation cocktail (Microscint-20, Packard, cat. # 20-133) was added to each well and the amount of radioactivity was counted in a top counter.

Compounds of this invention were active in this assay.

15 The GSK-3 β inhibitory activities (expressed as IC₅₀, the inhibitor concentration causing 50% inhibition of the activity in the control) of some compounds of the invention disclosed in Table I-IV were less than 2 μ m. Activities of certain specific compounds are shown below.

20

Compound	IC ₅₀ μ M
I-1	0.194
II-1	0.02
II-2	0.0264
II-4	0.0296
III-3	0.23
IV-1	0.1334

Example II

Inhibition of β -catenin degradation -- *in vitro* assay

The cell based GSK-3 β activity of compounds of this invention was determined by measuring β -catenin levels in Jurkat T-cells after treatment with the compounds of this invention using ELISA as follows.

Jurkat cells (5×10^5 cells/ml) were plated in 6-well plates (6 ml/well) and then treated with various concentrations of the compounds of this invention (preferably 1 nM-10 μ M) for 24 hours. At the end of the incubation, the cells were collected and washed once with PBS. The cells were then suspended in 0.3 ml Radioimmuno Precipitation Assay lysis (RIPA) buffer (Boehringer Mannheim, cat.# 1 920 693). After 3 freeze – thaw cycles, the cell extracts were centrifuged at 15,000 rpm for 10 min. The supernatant was collected and analyzed using ELISA assay as described below.

96 Microwell plates were coated overnight with capture antibody (mouse monoclonal anti- β -catenin, Zymed La., cat.# 13-8400, 100 μ l per well, containing 250 ng antibody) diluted in coating buffer (0.1 M NaHCO₃, pH 9.5). The wells were aspirated and washed 3 times with 300 μ l of wash buffer (PBS containing 0.05% Tween 20) and blocked with 200 μ l of assay diluent (PBS, 10% RBS, pH 7; PharMingen) and then incubated at room temperature for at least 72 h. The wells were washed again as described above. 100 μ l of the Jurkat cell supernatant and various concentrations of a β -catenin standard (Behrens et al. *Nature*, Vol. 382, p638 (1996)) were added to the wells and incubated for 2 h at room temperature. After incubation, the wells were washed and 100 μ l of anti- β -catenin antibody (Santa Cruz; β -catenin H-102, sc-7199, rabbit IgG) diluted in assay diluent (1:1250) was added to each well and the cells were incubated at room temperature for 2 h. After washing, 100 μ l of working detector (Sigma B5283, mouse monoclonal anti-rabbit IgG-Biotin) diluted in assay diluent (1:2000) was added into each well and incubated for 1 h at room temperature. 3,3',5,5'-Tetramethylbenzidine (PharMingen, Cat. # 2642KK) was used for color development. The reaction was stopped by adding 50 μ l of stop solution (2N

H₂SO₄) to each well. The plates were read with an ELISA plate reader at 570 nm within 30 min., of stopping the reaction.

The level of GSK-3 β inhibition was calculated by plotting the compound concentration versus β -catenin levels. The results are shown in Figure 1, confirming the effect of compounds of this invention on β -catenin levels.

Example III

Cytokine Secretion Assays —human T-cell assay

The effect of compounds of this invention on cytokine secretion levels from human CD4+ T-helper cells was determined as in Rogge *et. al.*, *J. Exp. Med.* 185, 825-831 (1997).

For this assay, human neonatal leukocytes were isolated from freshly collected, heparinized neonatal blood by Ficoll-Paque (Pharmacia Biotech, Uppsala, Sweden) density gradient centrifugation. To generate Th1 and Th2 cell lines, CD8+ T cells were removed by positive selection with anti-CD8 microbeads and magnetic activated cell sorting according to a protocol supplied by the manufacturer (Miltenyi Biotec, Bergisch Gladbach, Germany). On day 0, cells were pre-incubated with various concentrations of test compound for one day. The next day, cells were stimulated with 2 μ g/ml phytohemagglutinin (Wellcome, Beckenham, U.K.) in the presence of 2.5 ng/ml IL-12 (Hoffmann-La Roche, Nutley, NJ) and 200 ng/ml neutralizing anti-IL-4 antibody (no. 18500D; PharMingen, San Diego, CA) for Th1 cultures or 1 ng/ml IL-4 (PharMingen) and 2 μ g/ml neutralizing anti-IL-12 antibody 17F7 and 20C2 (kindly provided by M. Gately, Hoffmann-LaRoche) for Th2 cultures, respectively. The cells were washed on day 3 and expanded in complete RPMI 1640 medium (Life Technologies, Milan, Italy), supplemented with compounds of this invention, 5% FetalClone I (HyClone, Logan, UT), 2 mM L-glutamine, 1 mM sodium pyruvate, 100 U/ml penicillin-streptomycin, and containing 100 U/ml IL-2 (Hoffmann-La Roche). The cells were washed again on day 14 and 10⁵ cells were re-stimulated in 96-well round-bottom plates for 24 h with plate-bound anti-CD3 and anti-CD28

monoclonal antibodies (clone TR66; see Lanzavecchia, A., and D. Scheidegger, *Eur. J. Immunol.* 17:105-111 (1987)) to measure IFN-gamma, IL-4, and IL-13 in culture supernatants by ELISA assays (Gallati, H., I. et al., *J. Biol. Regul. Homeostatic Agents.* 1:109-118, (1987)). The ED₅₀ values (concentration of compound that inhibits cytokine secretion to 50% of the maximal value) were determined by fitting a sigmoidal curve to the plotted data.

Compounds of this invention were active in this assay and showed suppression of IL-4, and IL-13 secretion levels, while Interferon-gamma levels remained unchanged.

Example IV

Cytokine Secretion Assays ---murine T-cell assay

CD4+, CD62Lhi cells (naïve T-cells) are isolated from the spleens of Balb/C.Do11.10 OA-TCR transgenic mice (Murphy K.M. et al., *Science*, 250, 1720 (1990)) by Ficoll density gradient and Miltenyi magnetic immunobead separations. These naïve T-cells were grown in co-culture with irradiated Balb/C splenocytes (T:APC of 1:25) under neutral conditions (without the addition of differentiating cytokines). T-cells are stimulated with 300 nM ovalbumin peptide (NH₂-KISQAVHAAHAEINEAG-COOH) in the presence of different inhibitor concentrations (test compound), including controls with solvent only. At day 3 the cells were split 1:3, with inhibitors being added back to the medium to maintain the original concentration. On day 6, the cells were counted, washed, re-plated at a 1:25 ratio with irradiated Balb/C splenocytes, and re-stimulated with 300 nM ovalbumin peptide. On day 8, the supernatants were harvested and levels of IFN-gamma, IL-4, IL-5, and IL-13 were quantitated by ELISA (R&D Systems). The ED₅₀ values (concentration of compound that inhibits cytokine secretion to 50% of the maximal value) were determined by fitting a sigmoidal curve to the plotted data.

Compounds of this invention were active in this assay and led to a reduction in Th2 cytokine levels.

Example V

Inhibition of Eosinophil influx into the lungs of Ovalbumin sensitized
brown Norway rats— *in vivo* assay

5 The ability of the compounds of the invention to inhibit leukocyte
infiltration into the lungs was determined by measuring the inhibition of eosinophil
accumulation into the bronchioalveolar lavage (BAL) fluid of Ovalbumin (OA)
sensitized brown Norway rats after antigen challenge by aerosol. Briefly, male
brown-Norway rats were sensitized i.p. with 100 µg of OA in 0.2 ml alum on Day
10 0, Day 7, and Day 14. On Day 21, the rats were challenged with 1% OA for 45
min., and sacrificed 72 h later. Test compounds or only vehicle (control group)
were administered from the day before the third immunization until the end of the
study. At the time of sacrifice, rats were anesthetized (urethane, approx. 2 g/kg,
i.p.) and the lungs were lavaged with 3 x 3 ml BAL. The BAL fluid was analyzed
15 for total leukocyte number and differential leukocyte counts. The total leukocyte
number in an aliquot of the cells (20 µl) was determined by Coulter Counter. For
differential leukocyte counts, 50-200 µl of the samples were centrifuged in a
Cytospin and the slide stained with Diff-Quik. The proportions of monocytes,
eosinophils, neutrophils and lymphocytes were counted under light microscopy
20 using standard morphological criteria and expressed as a percentage.

Compounds of this invention were active in this assay and led to a reduction
in monocytes, eosinophils, neutrophils and lymphocytes infiltration into the lungs.

Example VI

Reduction of total Serum IgE and Ovalbumin specific IgE in Ovalbumin
sensitized A/J mice— *in vivo* assay

25 This protocol was designed to examine the effect of compounds on IgE
levels in the serum of Ovalbumin (OA) sensitized A/J mice. The primary endpoint
30 was IgE production during sensitization. Briefly, male A/J mice (20-25 g) were
sensitized by intraperitoneal injection of OA/Alum (10 µg in 0.2 ml Al(OH)₃; 2%)
on Day 0, and Day 7. On Day 14, the mice were anesthetized with urethane and

blood was drawn by cardiac puncture. Test compounds or only vehicle (control group) were administered from the day before the second OA/Alum injection until the end of the study. Total serum IgE and OA-specific IgE were measured by ELISA (Pharmingen, cat#2655KI, biotinylated ovalbumin for OA specific IgE) and compared between compound and vehicle treated groups.

Compounds of this invention were active in this assay and led to a reduction in IgE levels into the lungs.

10

Example VII

Differential Expression of TCF7 in Th1 and Th2 cells

CD4+, naïve T-cells were prepared as described in Example IV from Balb/C Do11.10 OA-TCR (+/+) transgenic mice and B10.D2 DO11.10 OA-TCR(+/-) transgenic mice (Guler M.L. et al., J. Immunol. 162, 1339-1347, 1999). Cells were harvested at day 5 after initial stimulation with 300nM ovalbumin peptide and mRNA was prepared (total RNA: Chomzynski and Sacchi, Anal. Biochem 162: 150-159, 1987, mRNA: Promega polyA tract) for expression analysis by Northern Blot. As hybridization probe clone AA119960 (Genbank) was labeled by random priming (GIBCO 18187-013) (Figure 2A). As shown in Figure 2A, expression of TCF7 transcripts was detected in mRNA from the B10.D2 preparation (Th-1 cells) while TCF7 transcripts were undetectable in the mRNA preparation from Balb/C T-cells (Th-2 cells). In a separate experiment, CD4+ naïve T-cells from Balb/C Do11.10 OA-TCR (+/+) transgenic mice were either stimulated with 300 nM ovalbumin peptide and interferon-gamma or ovalbumin peptide for 5 days. mRNA was isolated and used in a quantitative RT-PCR (Baranzini et al., Journal of Immunology. 165: 6576-6582, 2000) to determine relative levels of TCF7-mRNA between ovalbumin induced samples from Balb/C and B10.D2 and relative levels of ovalbumin treated Balb/C samples vs. ovalbumin and IFN-G treated samples from Balb/C CD4+ T-cells. TCF7 primers for the quantitative RT-PCR were: AGCTGCAGCCATATGATAGAA and CTTGAGTGTGCACTCAGCAA. Thus, as shown in Figure 2B, interferon gamma, a cytokine that promotes Th1

differentiation of Balb/c T-cells, induces the expression of TCF7. Both these experiments confirm that TCF7 levels are linked to the T-helper response. High levels of TCF7 expression appeared to be linked to a Th1 response, while low levels are linked to a Th2 response.

5

The foregoing invention has been described in some detail by way of illustration and example, for purposes of clarity and understanding. It will be obvious to one of skill in the art that changes and modifications may be practiced within the scope of the appended claims. Therefore, it is to be understood that the above description is intended to be illustrative and not restrictive. The scope of the invention should, therefore, be determined not with reference to the above description, but should instead be determined with reference to the following appended claims, along with the full scope of equivalents to which such claims are entitled.


10

15

All patents, patent applications and publications cited in this application are hereby incorporated by reference in their entirety for all purposes to the same extent as if each individual patent, patent application or publication were so individually denoted.

Claims

1. A compound represented by Formula (I):



(I)

wherein:

R¹ and R² independently represent hydrogen, alkyl, halogen, haloalkyl, alkylthio, hydroxy, alkoxy, cyano, nitro, amino, acylamino, monoalkylamino, or dialkylamino;

R³ represents hydrogen, alkyl, cycloalkyl, heteroalkyl, -COR⁷ (wherein R⁷ is hydrogen or alkyl), or phenyl optionally substituted with one or two substituents independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkylthio, hydroxy, alkoxy, cyano, nitro, amino, acylamino, monoalkylamino, and dialkylamino;

R⁴ and R⁵ independently represent hydrogen, alkyl, halogen, haloalkyl, alkylthio, hydroxy, alkoxy, cyano, nitro, amino, acylamino, monoalkylamino, or dialkylamino;

R⁶ is heteroalkyl, heterocyclyl, heterocyclylalkyl, heteroalkylsubstituted heterocyclyl, heteroalkylsubstituted cycloalkyl, heterosubstituted cycloalkyl, -OR⁸, -S(O)_nR⁸ (wherein n is an integer from 0 to 2; and R⁸ is heteroalkyl, heteroaralkyl, heterocyclyl, or heterocyclylalkyl), -NR⁹R¹⁰ (wherein R⁹ is hydrogen or alkyl and R¹⁰ is heterosubstituted cycloalkyl, heteroalkyl, heteroaralkyl, heterocyclyl, or heterocyclylalkyl), or -X-(alkylene)-Y-Z (wherein X is a covalent bond, -O-, -NH-, or -S(O)_{n1}- where n₁ is an integer from 0 to 2, Y is -O-, -NH-, or -S- and Z is heteroalkyl or SiR¹¹(R¹²)(R¹³) where R¹¹, R¹² and R¹³ are independently hydrogen

or alkyl.), or R⁶ together with R⁴ forms a methylenedioxy or ethylenedioxy group when they are adjacent to each other; or
a pharmaceutically acceptable salt thereof.

5 2. The compound according to claim 1, wherein

R³ represents hydrogen, alkyl, cycloalkyl, -COR⁷ (wherein R⁷ is hydrogen or alkyl), or phenyl optionally substituted with one or two substituents independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkylthio, hydroxy, alkoxy, cyano, nitro, amino, acylamino, monoalkylamino, and
10 dialkylamino;

R⁶ is heteroalkyl, heterocyclyl, heterocyclalkyl, heteroalkylsubstituted heterocyclyl, heteroalkylsubstituted cycloalkyl, heterosubstituted cycloalkyl, -OR⁸, -S(O)_nR⁸ (wherein n is an integer from 0 to 2; and R⁸ is heteroalkyl, heteroaralkyl, heterocyclyl, or heterocyclalkyl), -NR⁹R¹⁰ (wherein R⁹ is hydrogen or alkyl and
15 R¹⁰ is heteroalkyl, heteroaralkyl, heterocyclyl, or heterocyclalkyl), or -X-(alkylene)-Y-heteroalkyl (wherein X is a covalent bond, -O-, -NH-, or -S(O)_{n1}- where n1 is an integer from 0 to 2, and Y is -O-, -NH-, or -S-), or R⁶ together with R⁴ forms a methylenedioxy or ethylenedioxy group when they are adjacent to each other.

20


3. The compound according to claim 1 or 2, wherein R⁶ is at the 2, 3 or 4-position of the phenyl ring.

4. The compound according to any one of claims 1 to 3, wherein R⁶ is at the 3-position of the phenyl ring.
25

5. The compound according to any one of claims 1 to 4, wherein R⁶ is heteroalkyl, heterocyclalkyl, -OR⁸ (wherein R⁸ is heteroalkyl or heterocyclalkyl), -NHR¹⁰ (wherein R¹⁰ is heteroalkyl, heterosubstituted cycloalkyl, heterocyclyl, or heterocyclalkyl), or -X-(alkylene)-Y-heteroalkyl
30 (wherein X is a covalent bond, -O- or -NH- and Y is -O- or -NH).


6. The compound according to any one of claims 1 to 5, wherein R^4 and R^5 are at the 2 and the 6 positions of the phenyl ring and are independently of each other hydrogen or halogen.
- 5 7. The compound according to any one of claims 1 to 6, wherein R^1 and R^2 are hydrogen.
8. The compound according to any one of claims 1 to 6, wherein R^1 is at the 5-position of the indole ring and is halogen; R^2 is hydrogen.
- 10 9. The compound according to any one of claims 1 to 8, wherein R^3 is hydrogen or alkyl, R^6 is $-OR^8$ (wherein R^8 is heteroalkyl or heterocyclalkyl), $-NHR^{10}$ (wherein R^{10} is heteroalkyl, heterosubstituted cycloalkyl, heterocycl, or heterocyclalkyl), or $-X-(alkylene)-Y-heteroalkyl$ (wherein X is a covalent bond, -O- or -NH- and Y is -O- or -NH).
- 15 10. The compound according to any one of claims 1 to 8, wherein R^3 is hydrogen or alkyl, R^6 is $-OR^8$ (wherein R^8 is heteroalkyl or heterocyclalkyl), $-NHR^{10}$ (wherein R^{10} is heteroalkyl, heterocycl, or heterocyclalkyl), or $-X-(alkylene)-Y-heteroalkyl$ (wherein X is a covalent bond, -O- or -NH- and Y is -O- or -NH).
- 20 11. The compound according to any one of claims 1 to 10, wherein R^3 is alkyl.
- 25 12. The compound according to any one of claims 1 to 11, wherein R^3 is methyl.
13. The compound according to any one of claims 1 to 12, wherein R^4 and R^5 are independently of each other hydrogen, chloro, or fluoro.
- 30 14. The compound according to any one of claims 1 to 13, wherein R^4 and R^5 are hydrogen.

- 15 15. The compound according to any one of claims 1 to 14, wherein R⁶ is (RS), (R) or (S) 2,3-dihydroxypropyloxy, 3-hydroxypropyloxy, 2-aminoethyloxy, 3-aminopropyloxy, 2-morpholin-4-ylethyloxy, or (RS), (R) or (S) 2,2-dimethyl-1,3-dioxolan-4-ylmethyloxy.
- 10 16. The compound according to any one of claims 1 to 14, wherein R⁶ is (RS), (R) or (S) 2,3-dihydroxypropylamino, 2-hydroxyethylamino, 3-hydroxypropylamino, (RS), (R) or (S) 2,2-dimethyl-1,3-dioxolan-4-ylmethylanino, 2-hydroxy-1-hydroxymethylethylamino, 3-hydroxybutylamino, or tetrahydropyran-4-ylamino.
- 15 17. A method for preparing a compound of Formula (I) which comprises:
 (i) reacting a 3-indol-3-yl-4-phenylfuran-2,5-dione of formula:




where R¹-R⁶ are as defined in Claim 1 with ammonia to provide a compound of Formula (I); or

- (ii) reacting a compound of formula:



20 where R¹-R³ are as defined in Claim 1 and R is alkyl, with a compound of formula:



where R⁴-R⁶ are as defined in Claim 1, in the presence of a base; and

(iii) optionally converting a compound of Formula (I) to other compounds of Formula (I);

5 (iv) optionally converting the compound of Formula (I) prepared in Steps (i) or (ii) above, to the corresponding acid addition salt by treatment with an acid;

(v) optionally converting the compound of Formula (I) prepared in Steps (i) or (ii) above, to the corresponding free base by treatment with a base; and

10 (vi) optionally separating a mixture of stereoisomers of a compound of Formula (I) prepared in Steps (i) - (v) above, to give a single stereoisomer.

18. A medicament comprising a therapeutically effective amount of a compound according to any one of claims 1 to 16 and a pharmaceutically acceptable excipient.

15

19. The medicament according to claim 18 for the treatment of GSK-3 β mediated diseases selected from Alzheimer's disease, obesity, diabetes, atherosclerotic cardiovascular disease, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency, cancer, 20 allergy, and asthma in a mammal.

20. The medicament according to claim 18 or 19, wherein the disease is asthma.

21. The use of a compound according to any one of claims 1 to 16 for the 25 treatment of GSK-3 β mediated diseases selected from Alzheimer's disease, obesity, diabetes, atherosclerotic cardiovascular disease, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency, cancer, allergy, and asthma in a mammal.

22. The use according to claim 21, wherein the disease is asthma.

23. The use of a compound according to any one of claims 1 to 16 for the manufacture of medicaments comprising one or more compounds of formula I for the treatment of GSK-3 β mediated diseases selected from Alzheimer's disease, obesity, diabetes, atherosclerotic cardiovascular disease, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency, cancer, allergy, and asthma in a mammal.

24. The use according to claim 23, wherein the disease is asthma.

25. The use of an inhibitor of GSK-3 β for the treatment of a disease characterized by an excess of CD4+ Th2 cytokines.

26. The use according to claim 25, wherein the inhibitor of GSK-3 β is a compound according to any one of claims 1 to 16.

27. The use according to claim 25 or 26, wherein the disease is asthma, allergy or allergic rhinitis.

28. The use according to any one of claims 25 to 27, wherein the disease is asthma.




29. The use according to any one of claims 25 to 28, wherein the GSK-3 β inhibitor is at least 10 fold more selective for GSK-3 β relative to PKC.

30. The use of an inhibitor of GSK-3 β for the treatment of a disease characterized by an excess IgE production.

31. The use according to claim 30, wherein the inhibitor of GSK-3 β is a compound according to any one of claims 1 to 16.


32. The use according to claim 30 or 31, wherein the disease is asthma, allergy or allergic rhinitis.
33. The use according to any one of claims 30 to 32, wherein the disease is
5 asthma.
34. The use according to any one of claims 30 to 33, wherein the GSK-3 β inhibitor is at least 10 fold more selective for GSK-3 β relative to PKC.
- 10 35. The invention as herein before described, particularly with reference to the new compound, intermediates, uses and processes.

1/3

Figure 1:

2/3

FIGURE 2A



3/3

Relative Expression of TCF7 in CD4 T-cells




FIGURE 2 B.

THIS PAGE BLANK (USPTO)

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 February 2002 (07.02.2002)

PCT

(10) International Publication Number
WO 02/10158 A3

(51) International Patent Classification⁷: **C07D 405/14**,
A61K 31/404, C07D 403/04, 403/14

(21) International Application Number: PCT/EP01/08293

(22) International Filing Date: 18 July 2001 (18.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/221,058 27 July 2000 (27.07.2000) US

(71) Applicant: **F. HOFFMANN-LA ROCHE AG [CH/CH]**:
Grenzacherstrasse 124, CH-4070 Basle (CH).

(72) Inventors: **GONG, Leyi**: 2259 Armada Way, San Mateo,
CA 94404 (US). **GRUPE, Andrew**: 554 Jeter Street, Red-
wood City, CA 94062 (US). **PELTZ, Gary, Allen**: 110
Danbury Lane, Redwood City, CA 94062 (US).

(74) Agent: **POPPE, Regina**: Grenzacherstrasse 124,
CH-4070 Basle (CH).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).


Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
16 May 2002

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: 3-INDOLYL-4-PHENYL-1H-PYRROLE-2,5-DIONE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3BETA



(I)

(57) Abstract: The present invention relates to 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives of Formula (I), wherein R¹ to R⁶ have the value given in the specification. The compounds are useful as inhibitors of glycogen synthase kinase-3 β and, therefore, may be used for the treatment of GSK-3 β mediated diseases.

WO 02/10158 A3

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 01/08293

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D405/14 A61K31/404 C07D403/04 C07D403/14

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 00 38675 A (SMITHKLINE BEECHAM) 6 July 2000 (2000-07-06) claim 5; example B ---	1-35
Y	WO 00 21927 A (SMITHKLINE BEECHAM) 20 April 2000 (2000-04-20) claims; examples ---	1-35
Y	US 5 057 614 A (DAVIS ET. AL.) 15 October 1991 (1991-10-15) column 3, line 56 - line 64; claims; examples --- -/-	1-35

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

8 document member of the same patent family

Date of the actual completion of the international search

12 March 2002

Date of mailing of the international search report

19/03/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Helps, I

INTERNATIONAL SEARCH REPORT

Int. l. Application No
PCT/EP 01/08293

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	P.D. DAVIS ET. AL.: "Inhibitors of Protein Kinase C. 1. 2,3-Bisarylmaleimides." JOURNAL OF MEDICINAL CHEMISTRY, vol. 35, no. 1, January 1992 (1992-01), pages 177-84, XP002028954 table V	1-35
Y	M. P COGHLAN ET. AL.: "Selective Small Molecule Inhibitors of Glycogen Synthase Kinase 3 Modulate Glycogen Metabolism and Gene Transcription" CHEMISTRY AND BIOLOGY, vol. 7, no. 10, 2000, pages 793-803, XP001057051 figures 1-8	1-35
T	D.A.E. CROSS ET. AL.: "Selective Small Molecule Inhibitors of Glycogen Synthase Kinase 3 Activity Protect Primary Neurones from Death" JOURNAL OF NEUROCHEMISTRY, vol. 77, no. 1, April 2001 (2001-04), pages 94-102, XP001056683 figures 1-8	1-35

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. l. Application No

PCT/EP 01/08293

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0038675	A	06-07-2000	AU 1877700 A	31-07-2000
			EP 1140070 A1	10-10-2001
			WO 0038675 A1	06-07-2000
WO 0021927	A	20-04-2000	AU 6111699 A	01-05-2000
			EP 1119548 A1	01-08-2001
			WO 0021927 A2	20-04-2000
US 5057614	A	15-10-1991	AT 88704 T	15-05-1993
			AU 623630 B2	21-05-1992
			AU 2965889 A	10-08-1989
			CA 1320194 A1	13-07-1993
			CZ 8900752 A3	13-12-1995
			DE 58904168 D1	03-06-1993
			DK 55889 A	11-08-1989
			EP 0328026 A1	16-08-1989
			ES 2054890 T3	16-08-1994
			FI 890652 A ,B,	11-08-1989
			HU 49348 A2	28-09-1989
			IE 63489 B	03-05-1995
			IL 89167 A	27-02-1994
			JP 1233281 A	19-09-1989
			JP 1994298 C	22-11-1995
			JP 7030071 B	05-04-1995
			MC 2010 A	16-02-1990
			MX 14871 A	01-09-1993
			NO 890568 A ,B,	11-08-1989
			NZ 227850 A	26-11-1991
			PH 25185 A	27-03-1991
			PT 89661 A ,B	04-10-1989
			SK 75289 A3	06-05-1998
			SU 1799382 A3	28-02-1993
			YU 28489 A1	30-06-1991
			ZA 8900865 A	25-10-1989

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)